Apoptosis related Activators

Cat.No. Product Name Information Product Use Citations Product Validations
S0913 4',5,7-Trimethoxyflavone 4',5,7-Trimethoxyflavone (5,​7,​4'-​Trimethoxyflavone, TMF) is a flavonoid isolated from Kaempferia parviflora (KP) that induces apoptosis. This compound increases sub-G1 phase, DNA fragmentation, annexin-V/PI staining and Bax/Bcl-xL ratio, activates caspase-3 and degrades poly (ADP-ribose) polymerase (PARP) protein.
S3271 Caudatin Caudatin (Cauldatin), one species of C‑21 steroidal from Cynanchum auriculatum (C. auriculatum), effectively inhibits human glioma growth in vitro and in vivo through triggering cell cycle arrest and apoptosis.
S0931 Jaceosidin Jaceosidin, a flavonoid isolated from Artemisia vestita, possesses anti-tumor and anti-proliferative activities in many cancer cells. This compound induces apoptosis, activates Bax and down-regulates Mcl-1 and c-FLIP expression. It also inhibits COX-2 expression and NF-κB activation.
S3829 Isoalantolactone Isoalantolactone, one of the major sesquiterpene lactone compounds, is isolated from the roots of Anula helenium and possesses multiple biological activities including antifungal, anthelmintic, antimicrobial, anti-inflammatory, antitrypanosomal activities and antiproliferative effects on several cancer cell lines, such as colon, melanoma, ovary, prostate, lung, and leukemia. This compound is an apoptosis inducer, which also acts as an alkylating agent.
S3336 Heptadecanoic acid

Heptadecanoic acid (C17:0), an odd chain saturated fatty acid, significantly inhibits cell proliferation, and migration, while promoting apoptosis in PC‑9 and PC‑9/GR cells. This compound is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.

S6957 β-Elemene

β-Elemene ((-)-β-Elemene, Levo-β-elemene) is a sesquiterpene compound extracted from the herb Curcuma Rhizoma with antitumor activities. β-elemene can inhibit cell proliferation, arrest the cell cycle, and induce cell apoptosis or autophagy.

S3357 Elaidic acid

Elaidic acid is a major trans fatty acid that inhibits cell viability, elevates cell apoptosis by enhancing oxidative stress. This compound can be used as a pharmaceutical solvent.

S1078 MK-2206 Dihydrochloride MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. This compound induces autophagy and apoptosis in cancer cells. Phase 2.
Cell Res, 2025, 10.1038/s41422-025-01110-x
Cell Res, 2025, 10.1038/s41422-025-01085-9
Mol Cancer, 2025, 24(1):272
Verified customer review of MK-2206 Dihydrochloride
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. This compound also inhibits CK2 with IC50 of 98 nM. It is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Gut, 2025, gutjnl-2025-335163
Cell Mol Immunol, 2025, 22(5):541-556
Nat Commun, 2025, 16(1):1661
Verified customer review of LY294002
S2673 Trametinib (GSK1120212) Trametinib (GSK1120212, JTP-74057) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, and it does not inhibit the kinase activities of c-Raf, B-Raf, ERK1/2. This compound activates autophagy and induces apoptosis.
Cancer Cell, 2025, S1535-6108(25)00271-5
Signal Transduct Target Ther, 2025, 10(1):161
Signal Transduct Target Ther, 2025, 10(1):299
Verified customer review of Trametinib (GSK1120212)
S1460 SP600125 SP600125 (Nsc75890) is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc. This compound is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase AFLT3 and TRKA with of IC50 of 60 nM, 90 nM and 70 nM. It inhibits autophagy and activates apoptosis.
Nat Commun, 2025, 16(1):7156
Adv Sci (Weinh), 2025, 12(28):e2502634
Adv Sci (Weinh), 2025, 12(36):e00028
Verified customer review of SP600125
S1208 Doxorubicin (Adriamycin) Hydrochloride Doxorubicin (DOX) HCl is an antibiotic agent that inhibits human DNA topoisomerase II with IC50 of 2.67 μM. Doxorubicin reduces basal phosphorylation of AMPK. Doxorubicin is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation.This product may precipitate when dissolved in PBS solution. It is recommended to prepare the stock solution in pure water and dilute with either pure water or saline to obtain the working solution.Doxorubicin (Adriamycin) HCl can be used to induce animal models of kidney disease.
Cell Res, 2025, 35(6):437-452.
Nat Commun, 2025, 16(1):8873
Nat Commun, 2025, 16(1):509
Verified customer review of Doxorubicin (Adriamycin) Hydrochloride
S1120 RAD001 (Everolimus) Everolimus is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2025, 16(1):8189
Cell Rep Med, 2025, 6(11):102425
Verified customer review of RAD001 (Everolimus)
S1025 Gefitinib (ZD1839) Gefitinib is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. This compound promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Nat Commun, 2025, 16(1):7287
Nat Commun, 2025, 16(1):6451
Cell Rep Med, 2025, 6(2):101929
Verified customer review of Gefitinib (ZD1839)
S1008 AZD6244 (Selumetinib) Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.
Nat Commun, 2025, 16(1):4884
Cell Rep Med, 2025, S2666-3791(25)00102-8
Cell Rep, 2025, 44(6):115774
Verified customer review of AZD6244 (Selumetinib)
S1378 Ruxolitinib (INCB18424) Ruxolitinib (INCB18424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. This compound kills tumor cells through toxic mitophagy. It induces autophagy and enhances apoptosis.
Nature, 2025, 10.1038/s41586-025-08938-8
Nat Commun, 2025, 16(1):8409
Nat Commun, 2025, 16(1):492
Verified customer review of Ruxolitinib (INCB18424)
S1021 Dasatinib (BMS-354825) Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Cancer Cell, 2025, S1535-6108(25)00070-4
Mil Med Res, 2025, 12(1):83
Nat Commun, 2025, 16(1):4069
Verified customer review of Dasatinib (BMS-354825)
S7397 Sorafenib (BAY 43-9006) Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Mol Cancer, 2025, 24(1):34
Nat Commun, 2025, 16(1):509
Adv Sci (Weinh), 2025, 12(30):e04372
Verified customer review of Sorafenib (BAY 43-9006)
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1 (Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM, and it is found to inhibit autophagy while inducing apoptosis.
Nature, 2025, 10.1038/s41586-025-09745-x
Cell Res, 2025, 10.1038/s41422-025-01085-9
Signal Transduct Target Ther, 2025, 10(1):81
Verified customer review of Bafilomycin A1 (Baf-A1)
S1065 Pictilisib (GDC-0941) Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Signal Transduct Target Ther, 2025, 10(1):92
Nat Commun, 2025, 16(1):4884
Nat Commun, 2025, 16(1):7912
Verified customer review of Pictilisib (GDC-0941)
S1053 Entinostat (MS-275) Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. This compound induces autophagy and apoptosis. Phase 3.
Nat Commun, 2025, 16(1):2559
J Clin Invest, 2025, 135(11)e187490
Blood Cancer J, 2025, 15(1):108
Verified customer review of Entinostat (MS-275)
S1030 Panobinostat (LBH589) Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. It induces autophagy and apoptosis, and effectively disrupts HIV latency in vivo. Phase 3.
Cancer Cell, 2025, 43(4):776-796.e14
Signal Transduct Target Ther, 2025, 10(1):230
Nat Commun, 2025, 16(1):2173
Verified customer review of Panobinostat (LBH589)
S2215 DAPT DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.
Signal Transduct Target Ther, 2025, 10(1):334
Cell Host Microbe, 2025, 33(3):408-419.e8
Nat Commun, 2025, 16(1):8693
Verified customer review of DAPT
S1002 ABT-737 ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
Signal Transduct Target Ther, 2025, 10(1):161
J Hepatol, 2025, S0168-8278(24)02830-7
Cell Rep Med, 2025, S2666-3791(25)00057-6
Verified customer review of ABT-737
S2913 BAY 11-7082 (BAY 11-7821) BAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.
ACS Nano, 2025, 19(20):19057-19079
Adv Sci (Weinh), 2025, 12(28):e2502634
J Med Virol, 2025, 97(8):e70534
Verified customer review of BAY 11-7082 (BAY 11-7821)
S1133 Alisertib (MLN8237) Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay, and it has >200-fold higher selectivity for Aurora A than Aurora B. This compound induces cell cycle arrest, apoptosis and autophagy. Phase 3.
Nat Commun, 2025, 16(1):7832
EMBO J, 2025, 10.1038/s44318-025-00564-4
J Immunother Cancer, 2025, 13(1)e009316
Verified customer review of Alisertib (MLN8237)
S1225 Etoposide Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity which enhances double-strand and single-strand cleavage of DNA and reversibly inhibits repair by topoisomerase II binding. Etoposide induces autophagy, mitophagy and apoptosis.
Nature, 2025, 642(8068):785-795
Cell, 2025, 188(18):5081-5099.e27
Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1378
Verified customer review of Etoposide
S1109 BI 2536 BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.
Gut, 2025, gutjnl-2024-334274
Nat Commun, 2025, 16(1):1599
Genome Biol, 2025, 26(1):204
Verified customer review of BI 2536
S1714 Gemcitabine Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Nature, 2025, 10.1038/s41586-025-08974-4
Cell, 2025, S0092-8674(25)00556-2
Cancer Cell, 2025, 43(8):1530-1548.e9
Verified customer review of Gemcitabine
S1209 5-Fluorouracil (5-FU) 5-FU (5-Fluorouracil) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Nature, 2025, 10.1038/s41586-025-08974-4
Cancer Cell, 2025, S1535-6108(25)00223-5
Cell Stem Cell, 2025, S1934-5909(25)00265-6
Verified customer review of 5-Fluorouracil (5-FU)
S2247 Buparlisib (BKM120) Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Nat Commun, 2025, 16(1):1237
Cell Rep Med, 2025, 6(9):102356
Cell Death Dis, 2025, 16(1):210
Verified customer review of Buparlisib (BKM120)
S7024 Stattic Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM in cell-free assays, highly selectivity over STAT1. Stattic induces apoptosis.
Mol Cancer, 2025, 24(1):122
Nat Commun, 2025, 16(1):6807
Nat Commun, 2025, 16(1):5387
Verified customer review of Stattic
S1040 Sorafenib Tosylate (BAY 43-9006) Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Int J Oncol, 2025, 67(3)72
Nature, 2024, 629(8013):927-936
Cell Mol Life Sci, 2024, 81(1):238
Verified customer review of Sorafenib Tosylate (BAY 43-9006)
S1555 AZD8055 AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. This compound induces caspase-dependent apoptosis and also induces autophagy. Phase 1.
Signal Transduct Target Ther, 2025, 10(1):92
Plant Commun, 2025, 6(7):101389
J Cereb Blood Flow Metab, 2025, 0271678X251321641
Verified customer review of AZD8055
S1004 Veliparib (ABT-888) Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. This compound is inactive to SIRT2 and increases autophagy and apoptosis. Phase 3.
Nat Commun, 2025, 16(1):8476
Nat Commun, 2025, 16(1):1026
J Exp Med, 2025, 222(5)e20241184
Verified customer review of Veliparib (ABT-888)
S2853 PR-171 (Carfilzomib) Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Nat Genet, 2025, 57(10):2468-2481
Nat Commun, 2025, 16(1):765
Acta Biomater, 2025, S1742-7061(25)00677-4
Verified customer review of PR-171 (Carfilzomib)
S7781 Sunitinib (SU-11248) Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib is also a dose-dependent inhibitor of the autophosphorylation activity of IRE1α. Sunitinib induces autophagy and apoptosis.
Cancer Cell, 2025, 43(4):776-796.e14
Mol Cancer, 2025, 24(1):179
J Exp Clin Cancer Res, 2025, 44(1):290
Verified customer review of Sunitinib (SU-11248)
S1237 TMZ(Temozolomide) Temozolomide (TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. It is a DNA damage inducer in L-1210 and L-1210/BCNU cells. This compound induces apoptosis and exhibits antitumor activity.
Cancer Cell, 2025, S1535-6108(25)00223-5
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2025, 16(1):5676
Verified customer review of TMZ(Temozolomide)
S3020 Romidepsin (FK228) Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. This compound controls growth and induces apoptosis in neuroblastoma tumor cells.
J Extracell Vesicles, 2025, 14(2):e70042
Nucleic Acids Res, 2025, 53(20)gkaf1086
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of Romidepsin (FK228)
S1623 N-Acetylcysteine (NAC chemical, N-Acetyl-L-Cysteine) Acetylcysteine (N-acetyl-l-cysteine, NAC,N-acetylcysteine) is a ROS(reactive oxygen species) inhibitor that antagonizes the activity of proteasome inhibitors. It is also a tumor necrosis factor production inhibitor. Acetylcysteine(N-acetyl-l-cysteine) suppresses TNF-induced NF-κB activation through inhibition of IκB kinases. Acetylcysteine(N-acetyl-l-cysteine) induces apoptosis via the mitochondria-dependent pathway. Acetylcysteine(N-acetyl-l-cysteine) inhibits ferroptosis and virus replication.Solutions are unstable and should be fresh-prepared.
Signal Transduct Target Ther, 2025, 10(1):341
J Exp Med, 2025, 222(3)e20241248
Adv Sci (Weinh), 2025, 12(36):e06150
Verified customer review of N-Acetylcysteine (NAC chemical, N-Acetyl-L-Cysteine)
S1200 Decitabine Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Cancer Cell, 2025, S1535-6108(25)00223-5
Nat Commun, 2025, 16(1):4451
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of Decitabine
S1491 Fludarabine Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.
Cell Mol Immunol, 2025, 22(11):1478-1490
J Immunother Cancer, 2025, 13(7)e010926
Cell Rep, 2025, 44(4):115559
Verified customer review of Fludarabine
S2662 ICG-001 ICG-001 antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300. ICG-001 induces apoptosis.
Cancer Discov, 2025, 10.1158/2159-8290.CD-25-0629
Adv Sci (Weinh), 2025, 12(40):e05702
Cell Rep Med, 2025, 6(2):101927
Verified customer review of ICG-001
S2789 Tofacitinib (CP-690550) Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. This compound inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.
Cell Rep Med, 2025, S2666-3791(25)00102-8
EMBO Mol Med, 2025, 10.1038/s44321-025-00317-0
J Crohns Colitis, 2025, 19(6)jjaf076
Verified customer review of Tofacitinib (CP-690550)
S1191 Fulvestrant (ICI-182780) Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Nat Genet, 2025, 57(6):1452-1462
J Clin Invest, 2025, e188839
Cell Rep Med, 2025, 6(7):102192
Verified customer review of Fulvestrant (ICI-182780)
S1029 CC-5013 (Lenalidomide) Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
Signal Transduct Target Ther, 2025, 10(1):29
Nat Commun, 2025, 16(1):3800
Cell Rep Med, 2025, S2666-3791(25)00102-8
Verified customer review of CC-5013 (Lenalidomide)
S5243 Ruxolitinib (INCB18424) Phosphate Ruxolitinib Phosphate (INCB018424, INC424) is the phosphate salt form of Ruxolitinib. Ruxolitinib is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. Ruxolitinib kills tumor cells through toxic mitophagy. Ruxolitinib induces autophagy and enhances apoptosis.
Nat Commun, 2024, 15(1):10718
Cell Mol Life Sci, 2024, 82(1):14
Virol J, 2024, 21(1):23
S2235 Volasertib (BI6727) Volasertib is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.
Leukemia, 2025, 10.1038/s41375-025-02729-w
Cell Death Dis, 2025, 16(1):396
Cell Death Dis, 2025, 16(1):673
Verified customer review of Volasertib (BI6727)
S7747 Ro-3306 RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Nat Commun, 2025, 16(1):7898
Nat Commun, 2025, 16(1):6439
Nucleic Acids Res, 2025, 53(21)gkaf1179
Verified customer review of Ro-3306
S1042 Sunitinib (SU11248) Malate Sunitinib malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.
Nat Commun, 2025, 16(1):7853
CNS Neurosci Ther, 2025, 31(12):e70696
Sci Rep, 2025, 15(1):35889
Verified customer review of Sunitinib (SU11248) Malate
S1119 Cabozantinib (XL184) A potent VEGFR2 inhibitor with IC50 of 0.035 nM, Cabozantinib (XL184) also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. It induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Nat Commun, 2025, 16(1):509
Cell Death Differ, 2025, 10.1038/s41418-025-01510-x
Cell Death Dis, 2025, 16(1):76
Verified customer review of Cabozantinib (XL184)
S1786 Verteporfin Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Nat Commun, 2025, 16(1):4124
Adv Sci (Weinh), 2025, 12(44):e11726
Cell Death Differ, 2025, 10.1038/s41418-025-01446-2
Verified customer review of Verteporfin
S1526 Quizartinib (AC220) Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Quizartinib (AC220) induces apoptosis of tumor cells. Phase 3.
Signal Transduct Target Ther, 2025, 10(1):222
Leukemia, 2025, 39(9):2152-2162
EMBO Mol Med, 2025, 10.1038/s44321-025-00296-2
Verified customer review of Quizartinib (AC220)
S2248 Silmitasertib (CX-4945) Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, although it is less potent against Flt3, Pim1 and CDK1 (inactive in cell-based assay). This compound induces autophagy and promotes apoptosis. Phase 1/2.
Nat Cell Biol, 2025, 27(8):1272-1287
Nat Commun, 2025, 16(1):997
Metabolism, 2025, 162:156060
Verified customer review of Silmitasertib (CX-4945)
S1141 Tanespimycin (17-AAG) Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.
Cell Rep Med, 2025, S2666-3791(25)00102-8
Autophagy, 2025, 1-23.
Cell Commun Signal, 2025, 23(1):331
Verified customer review of Tanespimycin (17-AAG)
S1020 CI-1040 (PD184352) PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis.
Cell Host Microbe, 2025, 33(4):512-528.e7
Int J Mol Sci, 2025, 26(8)3536
Front Cell Dev Biol, 2025, 13:1601887
Verified customer review of CI-1040 (PD184352)
S8146 Mitomycin C Mitomycin C (Ametycine) is an antineoplastic antibiotic by inhibiting DNA synthesis, used to treat different cancers. Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
Cell, 2025, S0092-8674(25)00625-7
Biomaterials, 2025, 317:123090
EMBO J, 2025, 44(14):4013-4036
Verified customer review of Mitomycin C
S2704 LY2109761 LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM in a cell-free assay, respectively; shown to negatively affect the phosphorylation of Smad2. This compound blocks autophagy and induces apoptosis.
Cancer Res, 2025, 10.1158/0008-5472.CAN-25-3425
Research (Wash D C), 2025, 8:1002
J Nanobiotechnology, 2025, 23(1):748
Verified customer review of LY2109761
S2775 Nocodazole Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Adv Mater, 2025, e17493.
Nat Commun, 2025, 16(1):7898
EMBO J, 2025, 44(22):6556-6597
Verified customer review of Nocodazole
S2194 R406 R406(R406 besylate) is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. R406 induces apoptosis. Phase 1.
J Allergy Clin Immunol, 2025, 155(2):569-582
Int J Biol Sci, 2025, 21(12):5287-5304
Front Immunol, 2025, 16:1636917
Verified customer review of R406
S7818 Pexidartinib (PLX3397) Pexidartinib (PLX3397) is an oral, potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit (c-Kit), and FLT3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. This compound induces apoptosis and necrosis with antitumor activity. Phase 3.
Nat Commun, 2025, 16(1):6779
Nat Commun, 2025, 16(1):4590
Mol Ther, 2025, S1525-0016(25)00871-8
Verified customer review of Pexidartinib (PLX3397)
S1264 PD173074 PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.
Stem Cell Reports, 2025, 20(10):102640
Commun Biol, 2025, 8(1):125
Cell Stem Cell, 2024, S1934-5909(24)00294-7
Verified customer review of PD173074
S1241 Vincristine (Leurocristine) Sulfate Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Signal Transduct Target Ther, 2025, 10(1):230
Leukemia, 2025, 39(12):2881-2894
Cell Rep, 2025, 44(4):115434
Verified customer review of Vincristine (Leurocristine) Sulfate
S1567 Pomalidomide (CC-4047) Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Nat Commun, 2025, 16(1):6631
Cell Rep Med, 2025, S2666-3791(25)00102-8
J Med Virol, 2025, 97(8):e70537
Verified customer review of Pomalidomide (CC-4047)
S1052 Elesclomol (STA-4783) Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand and inhibits FDX1-mediated Fe-S cluster biosynthesis.Elesclomol (STA-4783) is a potent copper ionophore and can be used in the research of copper-dependent cell death (cuproptosis).
Nat Commun, 2025, 16(1):212
Cell Prolif, 2025, e70101.
J Transl Med, 2025, 23(1):127
Verified customer review of Elesclomol (STA-4783)
S7152 C646 C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM in a cell-free assay. Preferentially selective for p300 versus other acetyltransferases. C646 induces cell cycle arrest, apoptosis and autophagy.
Nat Commun, 2025, 16(1):4502
Nat Commun, 2025, 16(1):524
J Extracell Vesicles, 2025, 14(2):e70042
Verified customer review of C646
S1122 Mocetinostat (MGCD0103) Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.
Aging Cell, 2025, e70075
iScience, 2025, 28(3):112015
Cell Signal, 2025, 127:111587
Verified customer review of Mocetinostat (MGCD0103)
S1648 Cytarabine Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabine induces autophagy and apoptosis.
Nat Commun, 2025, 16(1):4133
Acta Pharm Sin B, 2025, 15(10):5277-5293
Cell Death Dis, 2025, 16(1):601
Verified customer review of Cytarabine
S1046 Vandetanib (ZD6474) Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Virulence, 2025, 16(1):2489751
bioRxiv, 2025, 2024.12.19.629395
Circulation, 2024, 150(7):563-576
Verified customer review of Vandetanib (ZD6474)
S1069 Luminespib (NVP-AUY922) Luminespib (AUY-922, NVP-AUY922, VER-52296) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Cell Rep Med, 2025, S2666-3791(25)00102-8
Autophagy, 2025, 1-23.
Cancers (Basel), 2025, 17(8)1341
Verified customer review of Luminespib (NVP-AUY922)
S8059 Nutlin-3a Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Nucleic Acids Res, 2025, 53(13)gkaf627
Cell Rep Med, 2025, 6(8):102284
Bone Res, 2025, 13(1):62
Verified customer review of Nutlin-3a
S8041 Cobimetinib (GDC-0973) Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing no significant inhibition when tested against a panel of more than 100 serine-threonine and tyrosine kinases. This compound induces apoptosis. Phase 3.
Cancer Cell, 2025, 43(3):482-502.e9
Hepatology, 2025, 10.1097/HEP.0000000000001439
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-3819
Verified customer review of Cobimetinib (GDC-0973)
S7153 10058-F4 10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression. 10058-F4 promotes a caspase-3-dependent apoptosis and modulates autophagy.
Nat Commun, 2025, 16(1):138
Int J Biol Sci, 2025, 21(6):2762-2779
Cell Death Dis, 2025, 16(1):601
Verified customer review of 10058-F4
S8049 Tubastatin A Tububastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). This compound promotes autophagy and increases apoptosis.
Nat Commun, 2025, 16(1):2559
Nat Commun, 2025, 16(1):2663
Cell Death Dis, 2025, 16(1):320
Verified customer review of Tubastatin A
S2741 Niraparib (MK-4827) Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. This compound can form PARP–DNA complexes resulting in DNA damage, apoptosis, and cell death. Phase 3.
Nat Commun, 2025, 16(1):4239
Cancer Commun (Lond), 2025, 45(12):1706-1733.
Neuro Oncol, 2025, noaf061
Verified customer review of Niraparib (MK-4827)
S1038 PI-103 PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM. This compound induces apoptosis in murine T-cell Lymphoma.
Nat Commun, 2025, 16(1):4828
Cell Rep, 2025, 44(5):115675
Genes (Basel), 2025, 16(8)892
Verified customer review of PI-103
S4001 Cabozantinib S-malate Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.
Sci Rep, 2025, 15(1):35889
bioRxiv, 2025, 2025.08.15.670608
Nat Neurosci, 2024, 10.1038/s41593-024-01604-8
Verified customer review of Cabozantinib S-malate
S1044 Temsirolimus (CCI-779) Temsirolimus is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Leukemia, 2025, 39(4):917-928
J Exp Clin Cancer Res, 2025, 44(1):290
Cell Rep, 2025, 44(5):115617
Verified customer review of Temsirolimus (CCI-779)
S2218 Torkinib (PP242) Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; this compound targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively. It induces mitophagy and apoptosis.
J Immunother Cancer, 2025, 13(3)e010753
Cell Rep, 2025, 44(4):115452
Int J Mol Sci, 2025, 26(16)7770
Verified customer review of Torkinib (PP242)
S1533 R406 (free base) R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. This compound triggers apoptosis. Phase 1.
Autophagy, 2025, 1-17.
EMBO Rep, 2025, 10.1038/s44319-025-00444-2
J Transl Med, 2024, 22(1):283
Verified customer review of R406 (free base)
S7007 MEK162 (Binimetinib, ARRY-162) Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Cell Rep Med, 2025, 6(2):101943
Cell Syst, 2025, 16(3):101229
Biochem Pharmacol, 2025, 235:116842
Verified customer review of MEK162 (Binimetinib, ARRY-162)
S7162 Mdivi-1 Mdivi-1 (Mitochondrial division inhibitor 1) is a selective cell-permeable inhibitor of mitochondrial division DRP1 (dynamin-related GTPase) and mitochondrial division Dynamin I (Dnm1) with IC50 of 1-10 μM. Mdivi-1 attenuates mitophagy and enhances apoptosis.
J Hazard Mater, 2025, 495:138854
Redox Biol, 2025, 86:103818
J Nanobiotechnology, 2025, 23(1):437
Verified customer review of Mdivi-1
S2736 Fedratinib (TG101348) Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Leukemia, 2025, 39(7):1678-1691
Front Immunol, 2025, 16:1514618
Cancer Immunol Immunother, 2025, 74(3):79
Verified customer review of Fedratinib (TG101348)
S8075 GANT 61 (NSC 136476) GANT61 (NSC 136476) is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation. GANT61 induces apoptosis and activates protective autophagy in LX-2 cells.
Nat Commun, 2025, 16(1):1267
Theranostics, 2025, 15(18):9819-9837
J Exp Clin Cancer Res, 2025, 44(1):22
Verified customer review of GANT 61 (NSC 136476)
S2626 Rabusertib (LY2603618) Rabusertib (LY2603618, IC-83) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosis in AML cell lines.
Nat Commun, 2025, 16(1):5706
Nat Commun, 2025, 16(1):480
Nucleic Acids Res, 2025, 53(12)gkaf544
Verified customer review of Rabusertib (LY2603618)
S2727 Dacomitinib (PF-299804) Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.
Cell Rep Med, 2025, 6(8):102284
Cell Oncol (Dordr), 2025, 10.1007/s13402-025-01097-y
Nat Commun, 2024, 15(1):2742
Verified customer review of Dacomitinib (PF-299804)
S2013 PF-573228 PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. This compound induces apoptosis.
Nat Commun, 2025, 16(1):2254
Nat Commun, 2025, 16(1):7287
Cell Rep Med, 2025, 6(2):101943
Verified customer review of PF-573228
S4701 2-DG (2-Deoxy-D-glucose) 2-DG (2-Deoxy-D-glucose), an analog of glucose, is a glycolytic inhibitor with antiviral activity. 2-Deoxy-D-glucose induces apoptosis and inhibits Herpes Simplex Virus type-1 (HSV-1) receptor expression.
Signal Transduct Target Ther, 2025, 10(1):341
Nat Commun, 2025, 16(1):212
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
Verified customer review of 2-DG (2-Deoxy-D-glucose)
S2783 Vistusertib (AZD2014) Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay, and is highly selective against multiple PI3K isoforms (α/β/γ/δ). It showed no or weak binding to the majority of kinases when tested at 1 μM. This compound induces proliferation suppression, apoptosis, cell cycle arrest, and autophagy in HCC cells with antitumor activity.
J Clin Invest, 2025, 135(18)e178446
NPJ Precis Oncol, 2025, 9(1):67
Sci Rep, 2025, 15(1):19445
Verified customer review of Vistusertib (AZD2014)
S1233 2-Methoxyestradiol (2-MeOE2) 2-Methoxyestradiol (2-MeOE2, NSC 659853, 2-ME2) depolymerizes microtubules and blocks HIF-1α nuclear accumulation and HIF-transcriptional activity. This compound also induces both autophagy and apoptosis in various carcinogenic cell lines.
Nat Commun, 2025, 16(1):4681
Int J Nanomedicine, 2025, 20:933-950
Theranostics, 2024, 14(13):5123-5140
Verified customer review of 2-Methoxyestradiol (2-MeOE2)
S7015 Birinapant (TL32711) Birinapant is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM in a cell-free assay, less potent to XIAP. This compound helps to induce apoptosis in latent HIV-1-infected cells. Phase 2.
Cell, 2025, S0092-8674(25)01233-4
Nat Commun, 2025, 16(1):7360
EMBO Mol Med, 2025, 10.1038/s44321-025-00201-x
Verified customer review of Birinapant (TL32711)
S7612 PX-478 Dihydrochloride PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Int J Biol Macromol, 2025, 332(Pt 1):148503
Elife, 2025, 13RP101912
Animals (Basel), 2025, 15(3)365
Verified customer review of PX-478 Dihydrochloride
S1108 TAE684 (NVP-TAE684) TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM, 100-fold more sensitive for ALK than InsR. This compound induces cell cycle arrest and apoptosis.
Adv Sci (Weinh), 2025, 12(17):e2416802
Sci Rep, 2024, 14(1):8200
EMBO Rep, 2023, 24(7):e56937
Verified customer review of TAE684 (NVP-TAE684)
S2788 Capmatinib (INC280) Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.
Mol Cancer, 2025, 24(1):272
Cell Rep Med, 2025, 6(9):102335
J Biomed Sci, 2025, 32(1):94
Verified customer review of Capmatinib (INC280)
S7536 Lorlatinib (PF-6463922) Lorlatinib (PF-6463922) is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. PF-06463922 induces apoptosis. Phase 1.
Leukemia, 2025, 10.1038/s41375-025-02682-8
Cell Death Dis, 2025, 16(1):194
Mol Oncol, 2025, 19(2):519-539
Verified customer review of Lorlatinib (PF-6463922)
S1159 Ganetespib (STA-9090) Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Nat Neurosci, 2025, 28(6):1174-1184
Redox Biol, 2025, 85:103672
J Nucl Med, 2025, jnumed.124.268961
Verified customer review of Ganetespib (STA-9090)
S1396 Resveratrol (trans-Resveratrol) Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases(LOX, IC50=2.7 μM), kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis.
Aging Cell, 2025, e70075
Biomed Pharmacother, 2025, 190:118393
Breast Cancer Res, 2025, 27(1):186
Verified customer review of Resveratrol (trans-Resveratrol)
S1792 Simvastatin (MK-733) Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis.
Nat Metab, 2025, 7(10):2018-2032
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
J Clin Invest, 2025, e190215
Verified customer review of Simvastatin (MK-733)
S1238 Tamoxifen Tamoxifen is an orally active, selective estrogen receptor modulator (SERM) which exhibits both estrogenic agonist and antagonist effects. It blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.
Cell Discov, 2025, 11(1):89
Nat Genet, 2025, 57(9):2192-2202
Cell Metab, 2025, 37(8):1715-1731.e11
Verified customer review of Tamoxifen
S1145 SNS-032 (BMS-387032) SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. This compound induces apoptosis.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Oncol Lett, 2025, 29(4):202
Int J Mol Sci, 2024, 25(2)886
Verified customer review of SNS-032 (BMS-387032)
S8341 TAK-243 (MLN7243) TAK-243 (MLN7243) is a potent, mechanism-based small-molecule inhibitor of the ubiquitin activating enzyme (UAE) with an IC50 of 1 ± 0.2 nM in the UBCH10 E2 thioester assay. It has minimal inhibitory activity in a panel of kinase and receptor assays, as well as on human carbonic anhydrase type I and type II. TAK-243 (MLN7243) induces ER stress, abrogates NFκB pathway activation and promotes apoptosis.
Mol Cell, 2025, 85(18):3505-3523.e17
Leukemia, 2025, 39(8):1997-2009.
J Nanobiotechnology, 2025, 23(1):717
S2796 WP1066 WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.
Cancer Med, 2025, 14(18):e71239
Nat Commun, 2024, 15(1):1987
Cancer Cell Int, 2024, 24(1):60
Verified customer review of WP1066
S8001 Ricolinostat (ACY-1215) Ricolinostat (ACY-1215, Rocilinostat) is a selective HDAC6 inhibitor with IC50 of 5 nM in a cell-free assay. It is >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2. Ricolinostat (ACY-1215) suppresses cell proliferation and promotes apoptosis. Phase 2.
Biomolecules, 2025, 15(1)76
Korean J Pain, 2025, 38(2):152-162
Cancer Immunol Immunother, 2024, 73(1):7
Verified customer review of Ricolinostat (ACY-1215)
S2824 TPCA-1 TPCA-1 (GW683965) is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1. TPCA-1 is also an inhibitor of STAT3 and enhances apoptosis.
Nat Genet, 2025, 10.1038/s41588-025-02221-2
EMBO J, 2025, 10.1038/s44318-025-00412-5
EMBO J, 2025, 10.1038/s44318-025-00561-7
Verified customer review of TPCA-1
S2285 Cryptotanshinone (Tanshinone C) Cryptotanshinone (Tanshinone C) is a STAT3 inhibitor with IC50 of 4.6 μM in a cell-free assay, strongly inhibiting phosphorylation of STAT3 Tyr705 with a small effect on STAT3 Ser727, but none against STAT1 nor STAT5. It also induces ROS-dependent autophagy and mitochondria-mediated apoptosis.
Am J Cancer Res, 2025, 15(7):2949-2969
Cancer Drug Resist, 2025, 8:45
Bone Joint Res, 2024, 13(4):137-148
Verified customer review of Cryptotanshinone (Tanshinone C)
S2893 NU7026 NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. This compound enhances G2/M cell arrest and apoptosis.
Nucleic Acids Res, 2025, 53(11)gkaf468
Nucleic Acids Res, 2025, 53(18)gkaf961
Redox Biol, 2025, 80:103504
Verified customer review of NU7026
S2817 Torin 2 Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. This compound inhibits ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively. It decreases cell viability and induces autophagy and apoptosis.
J Med Virol, 2025, 97(8):e70534
J Gen Virol, 2025, 106(3)002086
bioRxiv, 2025, 2025.09.24.678136
Verified customer review of Torin 2
S1080 SU11274 SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. This compound induces autophagy, apoptosis and cell cycle arrest.
Cell Death Dis, 2025, 16(1):76
World J Exp Med, 2025, 15(2):100443
Cancer Cell Int, 2024, 24(1):43
Verified customer review of SU11274
S1231 Topotecan HCl Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. This compound induces autophagy and apoptosis.
NPJ Precis Oncol, 2025, 9(1):306
Int J Mol Sci, 2025, 26(17)8494
Pharmaceuticals (Basel), 2025, 18(2)181
Verified customer review of Topotecan HCl
S2012 PCI-34051 PCI-34051 is a potent and specific HDAC8 inhibitor with IC50 of 10 nM in a cell-free assay. It has greater than 200-fold selectivity over HDAC1 and 6, more than 1000-fold selectivity over HDAC2, 3, and 10. PCI-34051 induces caspase-dependent apoptosis.
Nat Commun, 2025, 16(1):2663
Nat Commun, 2025, 16(1):515
Adv Sci (Weinh), 2025, 12(40):e05702
Verified customer review of PCI-34051
S2485 Mitoxantrone Dihydrochloride (NSC 301739) Mitoxantrone 2HCl is a dihydrochloride salt of Mitoxantrone. Mitoxantrone is an inhibitor of type II topoisomerase and protein kinase C (PKC) with IC50 of 8.5 μM for PKC. Mitoxantrone inhibits cell proliferative growth of MCF-7/wt cells with IC50 of 0.42 μM. Mitoxantrone also induces apoptosis.
Aging Cell, 2025, e70075
Biol Open, 2025, 14(9)bio062175
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Mitoxantrone Dihydrochloride (NSC 301739)
S5958 Metformin (1,1-Dimethylbiguanide) Metformin (1,1-Dimethylbiguanide), a widely used drug for treatment of type 2 diabetes, activates AMP-activated protein kinase (AMPK) in hepatocytes. Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
Signal Transduct Target Ther, 2025, 10(1):271
Theranostics, 2025, 15(17):9029-9046
Int J Biol Sci, 2025, 21(9):4231-4251
S1524 AT7519 AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. This compound also decrease GSK3β phosphorylation. It induces apoptosis. Phase 2.
Nat Struct Mol Biol, 2025, 10.1038/s41594-025-01517-5
Cell Rep Med, 2025, S2666-3791(25)00231-9
Nat Commun, 2024, 15(1):10028
Verified customer review of AT7519
S2391 Quercetin (Sophoretin) Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM. Quercetin induces mitophagy, apoptosis and protective autophagy. Phase 4.
Alzheimers Res Ther, 2025, 17(1):176
Cell Mol Life Sci, 2025, 82(1):164
Virol Sin, 2025, S1995-820X(25)00102-6
Verified customer review of Quercetin (Sophoretin)
S2743 PF-04691502 PF-04691502 (PF4691502) is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM in cell-free assays, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. This compound induces apoptosis. Phase 2.
Cell Death Discov, 2025, 11(1):266
Exp Gerontol, 2024, 186:112359
iScience, 2023, 26(9):107734
Verified customer review of PF-04691502
S8244 Etomoxir sodium salt Etomoxir sodium salt ((R)-(+)-Etomoxir sodium salt) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Etomoxir enhances palmitate-induced cell apoptosis.
J Clin Invest, 2025, e190215
Cell Commun Signal, 2025, 23(1):206
Cell Death Discov, 2025, 11(1):21
Verified customer review of Etomoxir sodium salt
S2753 Tivantinib Tivantinib is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. This compound induces a G2/M arrest and apoptosis.
Acta Neuropathol, 2024, 147(1):44
Eur J Cell Biol, 2024, 103(4):151457
Elife, 2023, 12e79432
Verified customer review of Tivantinib
S1848 Curcumin (Diferuloylmethane) Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase(IC50~25 μM)and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.
J Biol Chem, 2025, 301(7):110305
Mol Pain, 2025, 21:17448069251323668
BMC Immunol, 2025, 26(1):67
Verified customer review of Curcumin (Diferuloylmethane)
S1107 Danusertib (PHA-739358) Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. It induces apoptosis, cell cycle arrest, and autophagy. This compound is in Phase 2.
Elife, 2024, 12RP92324
Sci Rep, 2024, 14(1):4303
Environ Mol Mutagen, 2024, 10.1002/em.22604
Verified customer review of Danusertib (PHA-739358)
S2219 Momelotinib (CYT387) Momelotinib (CYT387, LM-1149, CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. This compound induces apoptosis and autophagy. Phase 3.
Cancer Med, 2025, 14(5):e70047
Antimicrob Agents Chemother, 2024, 68(4):e0135023.
Cell Rep, 2023, 42(9):113067
Verified customer review of Momelotinib (CYT387)
S2243 Degrasyn (WP1130) Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). This compound induces apoptosis and blocks autophagy.
Nat Commun, 2025, 16(1):628
Nat Commun, 2025, 16(1):1313
Cell Death Dis, 2025, 16(1):564
Verified customer review of Degrasyn (WP1130)
S1185 Ritonavir Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. This compound induces apoptosis.
Nature, 2025, 10.1038/s41586-025-09755-9
Vet Parasitol, 2025, 337:110471
Cell Chem Biol, 2024, S2451-9456(24)00396-9
Verified customer review of Ritonavir
S1680 Tetraethylthiuram disulfide (Disulfiram) Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH) with IC50 of 0.15 μM and 1.45 μM for hALDH1 and hALDH2, respectively. Disulfiram is used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram induces apoptosis. Disulfiram is also an inhibitor of pore formation by gasdermin D (GSDMD).
Nat Commun, 2025, 16(1):8083
Cell Rep Med, 2025, 6(9):102328
Leukemia, 2025, 39(9):2152-2162
Verified customer review of Tetraethylthiuram disulfide (Disulfiram)
S3604 Triptolide Triptolide is a diterpene triepoxide, immunosuppresive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway.
Mol Cell, 2025, S1097-2765(25)00316-8
Mol Cell, 2025, 85(15):2839-2853.e8
Chin Med, 2025, 20(1):122
Verified customer review of Triptolide
S1223 Epirubicin HCl Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase. Epirubicin induces apoptosis.
J Exp Clin Cancer Res, 2025, 44(1):299
J Exp Clin Cancer Res, 2025, 44(1):290
Eur J Pharm Biopharm, 2025, 216:114866
Verified customer review of Epirubicin HCl
S2714 LY411575 LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis.
Nat Commun, 2025, 16(1):5913
Dev Cell, 2025, S1534-5807(25)00468-X
Cell Rep, 2025, 44(4):115508
Verified customer review of LY411575
S4269 Vinorelbine Ditartrate (KW-2307) Vinorelbine ditartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin. Vinorelbine Tartrate exhibits anti-tumor activities via inducing the mitotic apoptosis, autophagy and inflammation.
Commun Biol, 2025, 8(1):152
Sci Rep, 2025, 15(1):11372
Cell Death Dis, 2024, 15(8):603
Verified customer review of Vinorelbine Ditartrate (KW-2307)
S4505 Vinblastine sulfate Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. This compound induces autophagy and apoptosis.
Biomed Pharmacother, 2025, 188:118203
Int J Mol Sci, 2025, 26(8)3864
J Mol Cell Biol, 2025, mjaf023
S7653 VS-4718 (PND-1186) VS-4718 (PND-1186) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM, which selectively promotes tumor cell apoptosis. Phase 1.
Cell Death Differ, 2025, 10.1038/s41418-025-01469-9
Front Immunol, 2025, 16:1596802
iScience, 2025, 28(1):111564
Verified customer review of VS-4718 (PND-1186)
S8375 AZD0156 AZD0156 is a potent and selective inhibitors of ATM kinase, with potential chemo-/radio-sensitizing and antineoplastic activities. AZD0156 prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells.
Cancer Cell, 2025, 43(8):1530-1548.e9
J Clin Invest, 2025, 135(8)e181659
Nucleic Acids Res, 2025, 53(12)gkaf544
S2746 AZ 628 AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM in cell-free assays, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc. AZ628 induces apoptosis.
J Biol Chem, 2025, 301(8):110454
PLoS One, 2024, 19(1):e0295629
Cell Genom, 2024, 4(2):100487
Verified customer review of AZ 628
S7888 Spautin-1 Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM. This compound enhances apoptosis.
Nat Commun, 2024, 15(1):9463
J Adv Res, 2024, S2090-1232(24)00025-0
Cancer Lett, 2024, 604:217258
Verified customer review of Spautin-1
S2198 SGI-1776 free base SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. SGI-1776 induces apoptosis and autophagy.
Cell Death Dis, 2024, 15(9):644
Mar Drugs, 2024, 22(10)444
Mol Cancer, 2023, 22(1):64
Verified customer review of SGI-1776 free base
S7625 Niraparib tosylate Niraparib tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. Niraparib increases formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death.
Cancer Res Commun, 2025, 10.1158/2767-9764.CRC-24-0515
Nat Commun, 2024, 15(1):9463
Nat Commun, 2024, 15(1):1041
Verified customer review of Niraparib tosylate
S7104 AZD1208 AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. This compound induces autophagy, cell cycle arrest and apoptosis. Phase 1.
Nat Commun, 2025, 16(1):256
Angiogenesis, 2024, 10.1007/s10456-024-09906-y
Cell Death Dis, 2024, 15(4):274
Verified customer review of AZD1208
S7885 SBI-0206965 SBI-0206965 is a highly selective autophagy kinase ULK1 inhibitor with IC50 of 108 nM, about 7-fold selectivity over ULK2. SBI-0206965 inhibits autophagy and enhances apoptosis in human glioblastoma and lung cancer cells.
Cell Res, 2025, 10.1038/s41422-025-01085-9
Theranostics, 2025, 15(1):258-276
Cell, 2024, 187(15):4043-4060.e30
Verified customer review of SBI-0206965
S7198 GSK-3 Inhibitor IX (BIO) BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.
Cell Rep, 2025, 44(3):115361
Development, 2025, 152(3)DEV204214
bioRxiv, 2025, 2025.04.11.648340
Verified customer review of GSK-3 Inhibitor IX (BIO)
S8401 Erdafitinib (JNJ-42756493) Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. This compound also binds to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit) and VEGFR-2 and induces cellular apoptosis.
Commun Biol, 2025, 8(1):394
Int J Mol Sci, 2025, 26(8)3525
J Clin Invest, 2024, 134(2)e169241
Verified customer review of Erdafitinib (JNJ-42756493)
S8078 Bardoxolone Methyl (RTA 402) Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.
J Clin Invest, 2025, 135(14)e176655
Redox Biol, 2025, 87:103885
Research (Wash D C), 2025, 8:0980
Verified customer review of Bardoxolone Methyl (RTA 402)
S1362 Rigosertib (ON-01910) Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay, showing 30-fold greater selectivity against Plk2 and no activity to Plk3. It inhibits the PI3K/Akt pathway, activates oxidative stress signals, and induces apoptosis in various cancer cells. This compound is in Phase 3.
Drug Resist Updat, 2025, 81:101251
Nat Commun, 2024, 15(1):2089
Environ Mol Mutagen, 2024, 10.1002/em.22604
Verified customer review of Rigosertib (ON-01910)
S1451 TCS7010 (Aurora A Inhibitor I) TCS7010 (Aurora A Inhibitor I) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B, and triggers apoptosis through the ROS-mediated UPR signaling pathway.
Cell Death Discov, 2025, 11(1):266
Cell Tissue Res, 2025, 10.1007/s00441-025-03992-0
Int J Mol Sci, 2022, 23(24)15573
Verified customer review of TCS7010 (Aurora A Inhibitor I)
S2759 Fimepinostat (CUDC-907) Fimepinostat (CUDC-907) is a dual PI3K and HDAC inhibitor targeting PI3Kα and HDAC1/2/3/10 with IC50 values of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. This compound induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.
Cell Death Discov, 2025, 11(1):172
J Am Heart Assoc, 2025, 14(1):e037400
Viruses, 2024, 16(5)775
Verified customer review of Fimepinostat (CUDC-907)
S7090 GSK-923295 GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. GSK923295 induces post-mitotic apoptosis. Phase 1.
Cancer Res, 2025, 85(15):2921-2938
Cancer Res, 2025, 10.1158/0008-5472.CAN-25-0999
Nat Cancer, 2024, 5(1):66-84
Verified customer review of GSK-923295
S7358 Poziotinib (NOV120101, HM781-36B) Poziotinib is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Clin Cancer Res, 2025, 31(14):3002-3018
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
iScience, 2024, 27(2):108839
S2606 Mifepristone (RU-486) Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.Mifepristone (RU486) can be used to induce animal models of Spontaneous Abortion.
Pharmacol Res, 2025, 215:107696
Cell Death Dis, 2025, 16(1):237
J Virol, 2025, 99(2):e0147224
Verified customer review of Mifepristone (RU-486)
S2310 Honokiol Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. This compound causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. It inhibits hepatitis C virus (HCV) infection. Phase 3.
J Adv Res, 2025, S2090-1232(25)00062-1
J Nanobiotechnology, 2025, 23(1):414
Oncol Lett, 2025, 29(4):191
Verified customer review of Honokiol
S7129 PYR-41 PYR-41 is the first cell-permeable inhibitor of ubiquitin-activating enzyme E1, with no activity at E2. This compound induces apoptosis.
Nat Commun, 2025, 16(1):3756
Redox Biol, 2025, 81:103522
EMBO Rep, 2025, 10.1038/s44319-025-00444-2
Verified customer review of PYR-41
S7785 Pemetrexed Disodium Hydrate Pemetrexed Disodium Hydrate (LY-231514) is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively. This compound stimulates autophagy and apoptosis.
iScience, 2024, 27(10):110862
Cell Rep, 2022, 38(9):110448
Front Pharmacol, 2022, 13:1032975
Verified customer review of Pemetrexed Disodium Hydrate
S2290 DHA (Dihydroartemisinin) Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin, is isolated from the traditional Chinese herb Artemisia annua. It induces autophagy and apoptosis by suppressing NF-κB activation.
iScience, 2025, 28(8):112972
Antimicrob Agents Chemother, 2025, e0047125.
Discov Oncol, 2025, 16(1):496
Verified customer review of DHA (Dihydroartemisinin)
S2696 Apitolisib (GDC-0980) Apitolisib (GDC-0980, RG7422, GNE 390) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. It also acts as a mTOR inhibitor with Ki of 17 nM in a cell-free assay, and is highly selective versus other PIKK family kinases. This compound activates autophagy and apoptosis simultaneously in pancreatic cancer cells. Phase 2.
Mol Cancer Ther, 2025, 10.1158/1535-7163.MCT-24-0693
Cell Oncol (Dordr), 2024, 10.1007/s13402-024-00939-5
Mol Oncol, 2024, 10.1002/1878-0261.13577
Verified customer review of Apitolisib (GDC-0980)
S2635 CCT128930 CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM in a cell-free assay, 28-fold greater selectivity for Akt2 than the closely related PKA kinase. This compound induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition. High dose of this chemical triggers cell apoptosis in HepG2 cells.
Proc Natl Acad Sci U S A, 2025, 122(27):e2504962122
Cell Rep, 2025, 44(5):115625
Nat Commun, 2024, 15(1):6150
Verified customer review of CCT128930
S1999 Sodium butyrate Sodium butyrate (NaB, Butanoic acid sodium salt), sodium salt of butyric acid, is a histone deacetylase inhibitor and competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This compound inhibits cell cycle progression, promotes differentiation, and induces apoptosis and autophagy in several types of cancer cells.
Cells, 2025, 14(9)627
Nat Commun, 2024, 15(1):4764
Nat Commun, 2024, 15(1):5209
Verified customer review of Sodium butyrate
S7165 UNC1999 UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. This compound is a potent autophagy inducer. It specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.
Cell Stem Cell, 2025, S1934-5909(25)00041-4
Cell Rep, 2025, 44(5):115673
bioRxiv, 2025, 2025.05.22.655558
Verified customer review of UNC1999
S1003 Linifanib (ABT-869) Linifanib (ABT-869, AL39324, RG3635) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). This compound induces autophagy and apoptosis, and is in Phase 3.
Biomed Pharmacother, 2024, 180:117533
Cell Death Discov, 2023, 9(1):57
Cancer Cell, 2022, S1535-6108(22)00312-9
Verified customer review of Linifanib (ABT-869)
S5971 Pemetrexed Pemetrexed (LY231514) is a novel antifolate and antimetabolite for thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT) with Ki of 1.3 nM, 7.2 nM and 65 nM in cell-free assays, respectively. This compound induces autophagy and apoptosis.
Nat Commun, 2025, 16(1):7853
Nat Commun, 2025, 16(1):8476
Sci Adv, 2025, 11(4):eadp4765
S1312 Streptozotocin (STZ) Streptozotocin (STZ) is a glucosamine-nitrosourea compound derived from Streptomyces achromogenes, which is a DNA-methylating, carcinogenic, antibiotic and diabetes inducing agent. It induces autophagy and apoptosis. This compound can be used to induce animal models of diabetes. Solutions are unstable and should be fresh-prepared.
Cell Rep Med, 2025, 6(8):102249
J Nanobiotechnology, 2025, 23(1):588
Int J Biol Macromol, 2025, 321(Pt 2):146174
Verified customer review of Streptozotocin (STZ)
S7895 Thapsigargin Thapsigargin is a potent, non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) with IC50 of 0.353 nM or 0.448 nM for the carbachol-evoked [Ca2+]i-transients with or without a KCl-prestimulation. Thapsigargin induces cell apoptosis. Thapsigargin is extracted from a plant, Thapsia garganica.
EMBO J, 2025, 44(4):1107-1130
Proc Natl Acad Sci U S A, 2025, 122(20):e2502652122
Cell Death Dis, 2025, 16(1):289
S7353 EPZ004777 EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM in a cell-free assay and demonstrates >1,200-fold selectivity for DOT1L over all other tested PMTs. EPZ004777 induces apoptosis.
NPJ Regen Med, 2024, 9(1):42
Cell Rep, 2023, 42(8):112885
Cell Rep, 2023, 42(6):112566
Verified customer review of EPZ004777
S1186 BIBR 1532 BIBR 1532 is a potent, selective, non-competitive telomerase inhibitor with IC50 of 100 nM in a cell-free assay. No inhibition of DNA and RNA polymerases, including HIV reverse transcriptase are observed at concentrations vastly exceeding the IC50 for telomerase. This compound induces apoptosis in cancer cells.
Biogerontology, 2024, 10.1007/s10522-024-10094-x
JCI Insight, 2023, 10.1172/jci.insight.170320
Cancers (Basel), 2023, 15(10)2673
Verified customer review of BIBR 1532
S7094 PF-3758309 PF-03758309 (PF-03758309) is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with Kd of 2.7 nM. This compound is antiproliferative and induces apoptosis in a HCT116 tumor model.
Cell Commun Signal, 2025, 23(1):135
Nat Commun, 2024, 15(1):3178
Oncogene, 2023, 42(39):2878-2891
Verified customer review of PF-3758309
S7177 PF-543 hydrochloride PF-543 hydrochloride, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. This compound induces apoptosis, necrosis, and autophagy.
Cell Death Discov, 2025, 11(1):29
FASEB J, 2025, 39(12):e70768
Sci Rep, 2025, 15(1):9786
Verified customer review of PF-543 hydrochloride
S7680 SP2509 SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. This compound induces apoptosis and promotes autophagy.
Cell Death Discov, 2025, 11(1):380
Cancer Res Commun, 2025, 5(9):1584-1598
bioRxiv, 2025, 2025.06.20.660795
Verified customer review of SP2509
S7369 4EGI-1 4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM. 4EGI-1 specifically inhibits the function of mTOR by blocking the activation of 4E-BP1. 4EGI-1 induces apoptosis.
Nat Commun, 2024, 15(1):4083
Nucleic Acids Res, 2024, gkae849
J Biol Chem, 2024, 300(11):107866
Verified customer review of 4EGI-1
S7038 Epoxomicin (BU-4061T) Epoxomicin (BU-4061T, Aids010837) is a selective proteasome inhibitor with anti-inflammatory activity, which primarily inhibits the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate. This compound promotes apoptosis and can be used to induce animal models of Parkinson's Disease.
Autophagy, 2025, 1-21.
Am J Hum Genet, 2025, 112(2):374-393
Acta Neuropathol, 2024, 148(1):14
Verified customer review of Epoxomicin (BU-4061T)
S7215 Losmapimod Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
J Neuroinflammation, 2025, 22(1):32
Nat Commun, 2024, 15(1):987
Int J Mol Sci, 2024, 25(13)7302
Verified customer review of Losmapimod
S7776 AKTi-1/2 (AKT Inhibitor VIII) Akti-1/2 (Akt Inhibitor VIII) is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3. Akti-1/2 induces apoptosis.
Nat Commun, 2025, 16(1):1313
Mol Metab, 2025, 100:102229
Life Sci Alliance, 2025, 8(11)e202503206
Verified customer review of AKTi-1/2 (AKT Inhibitor VIII)
S7396 Calpeptin Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. This compound attenuates apoptosis and intracellular inflammatory changes in muscle cells.
EMBO Mol Med, 2025, 17(12):3355-3376
Transl Psychiatry, 2025, 15(1):52
Mol Med, 2025, 31(1):166
Verified customer review of Calpeptin
S1452 Ispinesib (SB-715992) Ispinesib (SB-715992, CK0238273) is a potent, specific and reversible inhibitor of kinesin spindle protein (KSP) with Ki app of 1.7 nM in a cell-free assay, showing no inhibition to CENP-E, RabK6, MCAK, MKLP1, KHC or Kif1A. This compound induces mitotic arrest and apoptotic cell death.
Nat Cancer, 2024, 5(1):66-84
Cells, 2024, 13(7)607
Cancers (Basel), 2024, 16(23)4075
Verified customer review of Ispinesib (SB-715992)
S1156 Capecitabine Capecitabine is a tumor-selective fluoropyrimidine carbamate, which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU. Capecitabine treatment of HCT-15 cells causes condensation of DNA and induces apoptosis.
Cell Stem Cell, 2025, S1934-5909(25)00265-6
Genes Dis, 2024, 11(1):430-448
iScience, 2024, 27(10):110862
Verified customer review of Capecitabine
S1759 Pitavastatin (NK-104) Calcium Pitavastatin calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor. Pitavastatin Calcium attenuates AGEs-induced mitophagy via inhibition of ROS generation. Pitavastatin Calcium induces autophagy and apoptosis.
bioRxiv, 2025, 2025.08.10.669191
Nat Commun, 2024, 15(1):4099
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Pitavastatin (NK-104) Calcium
S5248 Apatinib (YN968D1) Apatinib (Rivoceranib, YN968D1) is a potent inhibitor of the VEGF signaling pathway with IC50 values of 1 nM, 13 nM, 429 nM and 530 nM for VEGFR-2, Ret (c-Ret), c-Kit and c-Src, respectively. Apatinib induces both autophagy and apoptosis.
Ann Dermatol, 2025, 37(4):228-240
Discov Oncol, 2025, 16(1):930
Cancer Cell, 2024, 42(4):535-551.e8
S8141 Cl-amidine Cl-amidine is an irreversible pan-peptidylarginine deiminase (PAD) inhibitor with IC50 values of 5.9 ± 0.3 μM, 0.8 ± 0.3 μM, 6.2 ± 1.0 μM for PAD4, PAD1 and PAD3, respectively. Cl-amidine induces apoptosis.
Immunity, 2025, S1074-7613(25)00069-X
Cell Rep, 2025, 44(2):115226
Nat Commun, 2024, 15(1):8663
S6871 Sodium oxamate Sodium oxamate (SO, Aminooxoacetic acid, Oxamic acid) is an inhibitor of lactate dehydrogenase (LDH) that specificly inhibits LDH‑A. This compound induces G2/M cell cycle arrest via downregulation of the CDK1/cyclin B1 pathway and promotes apoptosis through enhancement of mitochondrial ROS generation.
Adv Sci (Weinh), 2025, 12(8):e2411943
Nucleic Acids Res, 2025, 53(17)gkaf882
Cell Rep Med, 2025, 6(8):102292
S2820 TAE226 (NVP-TAE226) TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. This compound induces apoptosis.
Exp Ther Med, 2025, 29(5):93
Theranostics, 2022, 12(3):1097-1116
Proc Natl Acad Sci U S A, 2022, 119(32):e2201328119
Verified customer review of TAE226 (NVP-TAE226)
S7501 HO-3867 HO-3867, an analog of curcumin, is a selective STAT3 inhibitor that inhibits its phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs. This compound induces apoptosis.
Int J Biol Sci, 2025, 21(5):1914-1931
Biomedicines, 2023, 11(3)694
Evid Based Complement Alternat Med, 2023, 2023:8378581
Verified customer review of HO-3867
S1515 Pracinostat (SB939) Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. This compound induces apoptosis in tumor cells. Phase 2.
Cells, 2025, 14(11)852
EBioMedicine, 2024, 105:105211
Nat Commun, 2023, 14(1):5051
Verified customer review of Pracinostat (SB939)
S8615 Sodium Dichloroacetate (DCA) DCA (Sodium dichloroacetate), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
bioRxiv, 2025, 2025.04.03.647023
bioRxiv, 2025, 2025.08.24.671623
bioRxiv, 2025, 2023.08.11.552890
S2161 RAF265 (CHIR-265) RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM in cell-free assays. This compound induces cell cycle arrest and apoptosis. Phase 2.
bioRxiv, 2025, 2025.04.29.651188
Cancer Cell, 2022, S1535-6108(22)00312-9
iScience, 2022, 25(10):105182
Verified customer review of RAF265 (CHIR-265)
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. This compound also induces cell apoptosis.
Mol Cell, 2025, 85(15):2973-2987.e6
J Immunother Cancer, 2025, 13(10)e013269
Front Cell Dev Biol, 2025, 13:1566567
Verified customer review of JIB-04
S7076 T0901317 T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of 20nM for LXRα and 5 μM for FXR, respectively. This compound is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. It significantly suppresses cell proliferation and induces apoptosis.
J Clin Invest, 2025, 135(10)e186478
J Exp Med, 2025, 222(3)e20230647
Neurobiol Dis, 2025, 215:107094
Verified customer review of T0901317
S8246 RK-33 RK-33 is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.
Mol Cell, 2025, 85(3):585-601.e11
ASN Neuro, 2025, 17(1):2506406
J Immunol, 2025, vkaf281
S1972 Tamoxifen Citrate Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). This compound is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. It induces apoptosis and autophagy.
bioRxiv, 2025, 2025.07.21.666025
bioRxiv, 2024, 2023.05.10.540211
EMBO Rep, 2023, 24(5):e55835
Verified customer review of Tamoxifen Citrate
S1218 Clofarabine Clofarabine (Clolar) inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.
Invest Ophthalmol Vis Sci, 2025, 66(5):42
bioRxiv, 2025, 2025.04.25.650475
iScience, 2024, 27(10):110862
Verified customer review of Clofarabine
S2729 SB415286 SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β. This compound causes MM cell growth arrest and apoptosis.
bioRxiv, 2025, 2025.03.08.642085
Front Immunol, 2022, 13:880988
Sci Rep, 2022, 12(1):7
Verified customer review of SB415286
S8523 GSK2256098 GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. This compound inhibits cancer cell growth and induces apoptosis.
Front Immunol, 2025, 16:1596802
iScience, 2025, 28(4):112176
Sci Rep, 2025, 15(1):20840
S7960 Larotrectinib sulfate Larotrectinib sulfate is an oral potent and selective ATP-competitive inhibitor of tropomyosin receptor kinases (TRK). Larotrectinib inhibition of TRKs induces cellular apoptosis and G1 cell-cycle arrest.
iScience, 2024, 27(10):110862
Oncogenesis, 2023, 12(1):8
Front Pharmacol, 2022, 13:1032975
Verified customer review of Larotrectinib sulfate
S1244 Amuvatinib (MP-470) Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. It suppresses c-MET and c-RET, and is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2220
Hematol Oncol, 2025, 43(5):e70131
bioRxiv, 2024, 2023.11.21.568071
Verified customer review of Amuvatinib (MP-470)
S1692 Busulfan Busulfan is a cell cycle non-specific alkylating antineoplastic agent. It causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase activity. It also induces apoptosis. It is an immunosuppressive and myeloablative chemotherapeutic agent.Busulfan (NSC-750) can be used to induce animal models of Anemia.
Biomolecules, 2025, 15(2)297
J Immunother Cancer, 2024, 12(11)e009805
iScience, 2024, 27(10):110862
S8018 Nirogacestat (PF-03084014) Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay, and it induces apoptosis. Phase 2.
J Cell Biol, 2024, 223(10)e202305093
Biochem Pharmacol, 2024, 230(Pt 2):116577
Neurooncol Adv, 2024, 6(1):vdae188
Verified customer review of Nirogacestat (PF-03084014)
S7985 PIM447 (LGH447) Hydrochloride PIM447 (LGH447) Hydrochloride is a novel pan-PIM kinase inhibitor with Ki values of 6 pM, 18 pM, 9 pM for PIM1, PIM2, PIM3 respectively. It also inhibits GSK3β, PKN1, and PKCτ, but at a significantly lower potency with IC50 between 1 and 5 μM (>105-fold differential relative to the Ki on PIMs). PIM447 induces apoptosis.
Oncogene, 2024, 43(6):406-419
NPJ Precis Oncol, 2024, 8(1):152
Antiviral Res, 2024, 226:105891
Verified customer review of PIM447 (LGH447) Hydrochloride
S2812 (R)-(-)-Gossypol (AT-101) acetic acid (R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.
Protein Cell, 2024, pwad065
Int J Mol Sci, 2023, 24(7)6662
Leiden University The Netherlands, 2023,
Verified customer review of (R)-(-)-Gossypol (AT-101) acetic acid
S1807 Acyclovir (Aciclovir) Acyclovir (Aciclovir) is a synthetic nucleoside analogue active against herpesviruses, and it induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.
Int J Mol Sci, 2025, 26(15)7185
Virol Sin, 2025, S1995-820X(25)00102-6
Nat Commun, 2024, 15(1):9461
Verified customer review of Acyclovir (Aciclovir)
S2891 GW441756 GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2. This compound produces a relevant increase of caspase-3 that leads to apoptosis.
Cell Res, 2025, 10.1038/s41422-025-01098-4
Neurochem Int, 2025, 191:106072
Cells, 2023, 12(3)373
Verified customer review of GW441756
S7379 E-64 E-64 is an irreversible and selective cysteine protease inhibitor, and also inhibits papain, calpain, and cathepsins B and H, but not serine proteases or aspartic proteases. The IC50 for papain is 9 nM. This compound induces oxidative stress and apoptosis in Filarial Parasite.
Nat Commun, 2025, 16(1):5403
Elife, 2025, 14RP104057
bioRxiv, 2024, 2024.09.30.615241
S7846 Dubermatinib(TP-0903) Dubermatinib (TP-0903) is a potent and selective AXL Inhibitor with IC50 of 27 nM, and it is highly effective in inducing apoptosis.
Cancer Sci, 2025, 10.1111/cas.70151
Biol Direct, 2025, 20(1):77
Mol Oncol, 2024, 10.1002/1878-0261.13749
Verified customer review of Dubermatinib(TP-0903)
S7724 Eprenetapopt (APR-246) Eprenetapopt (APR-246, PRIMA-1MET) is a small organic molecule that has been shown to restore tumour-suppressor function primarily to mutant p53 and also to induce cell death in various cancer types. It induces apoptosis and autophagy.
Oncotarget, 2024, 15:614-633
J Cell Mol Med, 2024, 28(9):e18374
Cell Death Dis, 2023, 14(11):783
S1501 Mycophenolate mofetil Mycophenolate mofetil is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively. This compound induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Cell Metab, 2025, S1550-4131(25)00482-6
Cancers, 2025, 3389
Haematologica, 2024, 109(12):3989-4006
Verified customer review of Mycophenolate mofetil
S2077 Atorvastatin Calcium (CI-981) Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Atorvastatin Calcium induces apoptosis and autophagy.
J Exp Clin Cancer Res, 2025, 44(1):317
Journal of Experimental & Clinical Cancer Research, 2025, 317
Journal of Experimental & Clinical Cancer Research, 2025, 317
Verified customer review of Atorvastatin Calcium (CI-981)
S1576 Sulfasalazine Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. This compound is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. It induces ferroptosis, apoptosis and autophagy.
Med Oncol, 2024, 41(8):188
Adv Sci (Weinh), 2023, 10(20):e2300517
Proc Natl Acad Sci U S A, 2022, 119(36):e2117396119
S1497 Pralatrexate Pralatrexate is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines. This compound induces tumor cell apoptosis.
Cell Rep Med, 2025, S2666-3791(25)00102-8
Br J Haematol, 2024, 10.1111/bjh.19658
Discov Oncol, 2024, 15(1):709
Verified customer review of Pralatrexate
S1629 Orlistat Orlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. This compound treatment reduces proliferation, induces apoptosis and arrests cell cycle.
Cell Rep, 2025, 44(7):115901
Acta Pharmacol Sin, 2025, 10.1038/s41401-025-01477-y
J Cell Sci, 2024, 137(20)jcs262162
S8762 dBET6 dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.
Sci Adv, 2025, 11(49):eadu2292
J Nanobiotechnology, 2024, 22(1):692
Journal of Nanobiotechnology, 2024, 692
S7793 Purvalanol A Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. This compound induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Biomacromolecules, 2024, 10.1021/acs.biomac.4c00672
Cancers (Basel), 2023, 10.3390/cancers15225424
Verified customer review of Purvalanol A
S7097 HSP990 (NVP-HSP990) HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM, and it induces cell cycle arrest and apoptosis.
Autophagy, 2025, 1-23.
J Virol, 2025, e0050225
J Virol, 2025, 99(7):e0050225
Verified customer review of HSP990 (NVP-HSP990)
S7963 TIC10 (ONC201) TIC10 (ONC201) inactivates Akt and ERK to induce TNF-related apoptosis-inducing ligand (TRAIL) through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
Elife, 2023, 12e85898
J Biol Chem, 2023, S0021-9258(23)02442-0
Neoplasia, 2023, 39:100894
Verified customer review of TIC10 (ONC201)
S1487 PHA-793887 PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. This compound induces cell-cycle arrest and apoptosis. Phase 1.
Cell Rep Med, 2025, S2666-3791(25)00231-9
PLoS One, 2025, 20(6):e0324443
J Biol Chem, 2024, 300(11):107880
Verified customer review of PHA-793887
S8808 DC661 DC661 is a potent palmitoyl protein thioesterase 1 (PPT1) inhibitor. DC661 is capable of deacidifying the lysosome and inhibiting autophagy significantly better than HCQ. DC661 induces apoptosis.
Cell Signal, 2025, 134:111879
Autophagy, 2024, 1-13.
Cell Mol Life Sci, 2024, 82(1):27
S7362 AZD5582 AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15
EMBO J, 2025, 10.1038/s44318-025-00412-5
Cell Rep, 2024, 43(7):114400
Cell Death Dis, 2023, 14(9):599
S7276 SGI-1027 SGI-1027 (DNA Methyltransferase Inhibitor II) is a DNMT inhibitor with IC50 of 6, 8, 7.5 μM for DNMT1, DNMT3A, and DNMT3B in cell-free assays, respectively. This compound induces apoptosis.
Eur J Pharm Sci, 2024, 197:106767
Parasites Hosts Dis, 2024, 62(1):98-116
Int J Biol Sci, 2022, 18(11):4372-4387
Verified customer review of SGI-1027
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. This compound shows great selectivity against a panel of 50 different kinases. 10 μM of this chemical fails to significantly inhibit of any of these kinases. It induces apoptosis.
Front Immunol, 2025, 16:1558845
Frontiers in Immunology, 2025, 1558845
bioRxiv, 2025, nan
S8400 Mivebresib (ABBV-075) Mivebresib (ABBV-075) is a novel BET family bromodomain inhibitor. It binds bromodomains of BRD2/4/T with similar affinities (Ki of 1-2.2 nM) and highly selective for 18 bromodomain proteins tested (Kd > 1 μM; more than 600-fold selectivity vs. BRD4), but exhibits roughly 10-fold weaker potency towards BRD3 (Ki of 12.2 nM) and has moderate activity towards CREBBP (Kd = 87 μM; 54-fold selectivity vs. BRD4). Mivebresib(ABBV-075) efficiently triggers apoptosis in various tumor cell.
bioRxiv, 2025, 2025.03.25.645256
Cell Commun Signal, 2024, 22(1):415
Cancers (Basel), 2024, 16(6)1125
S1118 XL147 analogue XL147 analogue (SAR245408) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. This compound induces apoptosis. Phase 1/2.
J Pers Med, 2022, 12(2)258
Hum Cell, 2022, 10.1007/s13577-022-00671-y
Journal of Personalized Medicine, 2022, 258
Verified customer review of XL147 analogue
S1181 ENMD-2076 ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. This compound inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0.025 to 0.7 μM, which induces apoptosis and G2/M phase arrest. Phase 2.
Int J Biol Macromol, 2025, 292:139119
Cell, 2021, 184(2):334-351.e20
Cancer Discovery, 2021, 2544-2563
Verified customer review of ENMD-2076
S1299 Floxuridine (FUDR) Floxuridine (FUDR), a prodrug that is rapidly catabolized to 5-fluorouracil in vivo, is used to treat various cancers, particularly metastases to the liver. It inhibits Poly(ADP-Ribose) polymerase and induces DNA damage and apoptosis. This compound also has antiviral effects against HSV and CMV.
Toxicol Lett, 2025, 406:31-37
iScience, 2024, 27(10):110862
Cancer Cell, 2023, 41(5):933-949.e11
S8024 Tyrphostin AG 1296 Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR. Tyrphostin AG1296 inhibits FGFR and c-Kit with IC50 of 12.3 μM and 1.8 μM in Swiss 3T3 cells. Tyrphostin AG1296 induces dramatic apoptosis in A375R cells.
Dev Cell, 2022, 57(12):1466-1481.e6
Front Pharmacol, 2021, 12:804327
Mol Med Rep, 2021, 23(4):1
Verified customer review of Tyrphostin AG 1296
S8402 KRIBB11 KRIBB11 abolishes the heat shock-induced luciferase activity with an IC50 of 1.2 μM. It is an inhibitor of the transcription factor Heat Shock Factor 1 (HSF1). This compound induces growth arrest and apoptosis.
Mil Med Res, 2024, 11(1):41
Nanomaterials (Basel), 2024, 14(19)1564
Nat Commun, 2023, 14(1):6473
S8317 3BDO 3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signaling pathway. It inhibits autophagy in HUVECs. This compound inhibits oxLDL-induced apoptosis.
Cancer Immunology Research, 2024, 631–643
NPJ Parkinsons Dis, 2024, 10(1):52
Adv Sci (Weinh), 2023, 10(13):e2205436
S7204 Fosbretabulin (Combretastatin A4 Phosphate) Disodium Fosbretabulin (Combretastatin A4 Phosphate) Disodium is the water-soluble prodrug of Combretastatin A4 (CA4), which is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM in a cell-free assay. Fosbretabulin Disodium inhibits the polymerization of tubulin with IC50 of 2.4 μM, and also disrupts tumor vasculature. Fosbretabulin disodium induces mitotic arrest and apoptosis in endothelial cells. Phase 3.
Cell Rep, 2025, 44(5):115617
Front Oncol, 2023, 13:1249524
Cell, 2020, 182(3):685-712.e19
Verified customer review of Fosbretabulin (Combretastatin A4 Phosphate) Disodium
S1443 Zileuton Zileuton is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used to decrease the symptoms of asthma. This compound induces apoptosis while inhibits ferroptosis.
Nat Commun, 2024, 15(1):8663
J Transl Med, 2023, 21(1):923
Cancer Sci, 2023, 10.1111/cas.15994
Verified customer review of Zileuton
S7255 Onvansertib (NMS-1286937, NMS-P937) Onvansertib (NMS-1286937, NMS-P937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. This compound potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1.
Nat Commun, 2025, 16(1):3605
J Mass Spectrom, 2025, 60(5):e5137
Cancer Res Commun, 2025, 5(4):648-667
S7678 Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.
Front Pharmacol, 2025, 16:1539032
J Immunother Cancer, 2024, 12(11)e009805
Ren Fail, 2024, 46(2):2392849
Verified customer review of Sacubitril/valsartan (LCZ696)
S8117 GMX1778 GMX1778 is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and Kd of < 25 nM and 120 nM, respectively. This compound induces programmed cell death with apoptotic features. Phase 1.
Nat Commun, 2025, 16(1):2513
Nature Communications, 2025, 2513
bioRxiv, 2025, 2025.04.25.650475
Verified customer review of GMX1778
S7889 Xanthohumol Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. This compound inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. It is also a potent antiviral agent against a series of DNA and RNA viruses. This chemical induces growth inhibition and apoptosis in cancer cells. Phase 1.
Oncotarget, 2025, 16:532-544
J Cell Sci, 2024, 137(20)jcs262162
Antiviral Res, 2022, 207:105416
S7465 FTI 277 HCl FTI 277 HCl is a potent and selective farnesyltransferase (FTase) inhibitor with IC50 of 500 pM, about 100-fold selectivity over the closely related GGTase I. This compound inhibits cell growth and induces apoptosis. This chemical is effective in clearing HDV viremia.
EMBO J, 2025, 44(4):1185-1219
BMC Biol, 2025, 23(1):233
PLoS One, 2025, 20(9):e0331440
Verified customer review of FTI 277 HCl
S2214 AZ 960 AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of this compound for JAK2 over JAK3. This chemical induces apoptosis and growth arrest.
Front Oncol, 2025, 15:1589396
Adv Biol Regul, 2025, 95:101072
Antimicrob Agents Chemother, 2024, 68(4):e0135023.
Verified customer review of AZ 960
S8365 Apoptozole Apoptozole (Apoptosis Activator VII) is an inhibitor of heat shock protein 70(HSP70) and Hsc70 with dissociation constants Kd of 0.14 μM and 0.21 μM, respectively. It induces caspase-dependent apoptosis.
Nutrients, 2023, 992
Nutrients, 2023, 15(4)992
Journal of Virology, 2023, e00128-23
Verified customer review of Apoptozole
S2271 Berberine chloride Berberine chloride is a quaternary ammonium salt from the group of isoquinoline alkaloids. This compound activates caspase 3 and caspase 8, cleavage of poly ADP-ribose polymerase (PARP) and the release of cytochrome c. It decreases the expression of c-IAP1, Bcl-2 and Bcl-XL. This chemical induces apoptosis with sustained phosphorylation of JNK and p38 MAPK, as well as generation of the ROS. It is a dual topoisomerase I and II inhibitor. It is also a potential autophagy modulator.
J Cardiovasc Dev Dis, 2025, 12(7)278
Adv Healthc Mater, 2023, e2300591.
Transl Oncol, 2023, 35:101712
S7652 OTS514 hydrochloride OTS514 is a highly potent TOPK(T-LAK cell-originated protein kinase) inhibitor with an IC50 value of 2.6 nM. OTS514 induces cell cycle arrest and apoptosis.
Exp Mol Med, 2022, 54(7):999-1010
Mol Oncol, 2021, 15(12):3721-3737
Oncogenesis, 2021, 10(1):9
S7421 CGP 57380 CGP 57380 is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like kinases. This compound upregulates β-catenin and potentiates radiation-induced apoptosis.
Sci Rep, 2025, 15(1):1973
Scientific Reports, 2025, 1973
Cell Communication and Signaling, 2023, 107
Verified customer review of CGP 57380
S7648 OTS964 OTS964 is a potent TOPK inhibitor with high affinity and selectivity and IC50 value is 28 nM. This compound is also a potent inhibitor of the cyclin-dependent kinase CDK11 with Kd of 40 nM. This chemical treatment activates autophagy in glioma cells and induces apoptosis of human lung cancer cells in mouse xenografts.
Molecular Oncology, 2025, nan
Mol Oncol, 2025, 10.1002/1878-0261.70143
Sci Adv, 2025, 11(4):eadq2395
S9785 Fatostatin

Fatostatin (125B11), a diarylthiazole derivative, is a specific inhibitor of Sterol regulatory element binding proteins (SREBPs) activation. This compound binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. It suppresses growth and enhances apoptosis in cancer cells.

J Transl Med, 2025, 23(1):1055
iScience, 2025, 28(8):113097
Oncol Lett, 2025, 29(4):175
S9141 Berbamine Berbamine (BA), a traditional Chinese medicine extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. This compound induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).
Vet Res, 2025, 56(1):37
Veterinary Microbiology, 2025, 110356
Vet Microbiol, 2025, 301:110356
S8663 Takinib (EDHS-206) Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib induces apoptosis.
Gut Microbes, 2024, 16(1):2402543
Chemosphere, 2024, 368:143785
Nat Commun, 2023, 14(1):143
S8058 Riviciclib hydrochloride (P276-00) Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. This compound induces apoptosis. Phase 2/3.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Cell Reports Medicine, 2025, 102158
Arthritis Research & Therapy, 2021, 47
Verified customer review of Riviciclib hydrochloride (P276-00)
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). This compound is also a novel G2 checkpoint abrogator. It induces apoptosis.
iScience, 2025, 28(5):112292
Signal Transduct Target Ther, 2024, 9(1):181.
Nat Commun, 2024, 15(1):2089
S7106 AZD3463 AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. This compound suppresses cell viability by inducing both cell apoptosis and autophagy.
Sci Rep, 2024, 14(1):8200
bioRxiv, 2023, 10.1101/2023.12.19.572304
Burns Trauma, 2020, 8:tkaa025
Verified customer review of AZD3463
S9700 Tapinarof (Benvitimod, WBI-1001) Tapinarof (GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505) is a natural agonist of aryl hydrocarbon receptor (AhR) and induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) with EC50 of 0.16 nM. Tapinarof induces cellular apoptosis in CD4+ T cells in a dosedependent manner with IC50 of 5.2 μM.
Pharmaceutics, 2025, 17(6)731
Molecular Cancer Therapeutics, 2024, MCT-24-0211
Mol Cancer Res, 2024, 10.1158/1541-7786.MCR-24-0151
S8432 Troglitazone (CS-045) Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Troglitazone prevents RSL3-induced ferroptosis and lipid peroxidation in Pfa1 cells.
CNS Neuroscience & Therapeutics, 2024, e14911
CNS Neurosci Ther, 2024, 30(8):e14911
International Journal of Molecular Medicine, 2024, 37
S4484 Trametinib DMSO solvate (GSK1120212B) Trametinib DMSO solvate is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assay. Trametinib activates autophagy and induces apoptosis.
Antibiotics (Basel), 2024, 13(9)909
JID Innov, 2024, 4(2):100248
Cell Rep, 2022, 38(7):110374
S0709 Tubastatin A TFA Tubastatin A TFA (Tubastatin A trifluoroacetate salt) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Nature Communications, 2025, 2559
Communications Biology, 2025, 607
Cell Mol Life Sci, 2023, 80(11):333
S8820 Unesbulin (PTC596) Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that accelerates BMI-1 degradation. This compound downregulates MCL-1 and induces p53-independent mitochondrial apoptosis. IC50 values at 72 hours ranged from 68 to 340 nM in mantle cell lymphoma (MCL) cell lines.
Cell Rep Med, 2025, S2666-3791(25)00150-8
NPJ Precis Oncol, 2024, 8(1):68
PLoS One, 2023, 18(2):e0277313
S9631 Puromycin aminonucleoside Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.This compound can be used to induce animal models of Kidney Disease.
PLoS Pathog, 2025, 21(9):e1013549
bioRxiv, 2025, 2025.08.15.670603
mBio, 2024, 15(12):e0194524
S8149 NSC348884 NSC348884, as a nucleophosmin inhibitor, inhibit cell proliferation and induce apoptosis in various cancer cell lines with IC50 values ranging from 1.4-4 µM.
Mol Cell, 2025, S1097-2765(25)00409-5
Front Immunol, 2022, 13:956991
Nat Commun, 2020, 3;11(1):1669
S5144 Neferine Neferine ((R)-1,2-Dimethoxyaporphine), a natural component of Nelumbo nucifera, has antitumor efficiency. It induces apoptosis in renal cancer cells. This compound prevents autophagy through activation of Akt/mTOR pathway and Nrf2 in muscle cells. It strongly inhibits NF-κB activation. It possesses a number of therapeutic effects such as anti-diabetic, anti-aging, anti-microbial, anti-thrombotic, anti-arrhythmic, anti-inflammatory and even anti-HIV.
J Cosmet Dermatol, 2024, 10.1111/jocd.16587
Bone Res, 2022, 10(1):27
Cell Death Dis, 2022, 13(11):1000
S0278 SU5614 SU5614 (Chloro-SU5416, Chloro-Semaxanib) is a small molecule receptor tyrosine kinases (RTK) inhibitor of VEGFR-2, c-kit, and both wild-type and mutant FLT3. This compound reduces cell proliferation and induces apoptosis.
Am J Pathol, 2024, S0002-9440(24)00326-2
Frontiers in Cell and Developmental Biology, 2022, 797047
Advanced Science, 2021, 2101848
S8156 ARS-853 ARS-853 is a selective, covalent KRAS(G12C) inhibitor that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation. This compound also induces apoptosis.
Sci Rep, 2023, 10.1038/s41598-023-46623-w
Cell Mol Gastroenterol Hepatol, 2022, S2352-345X(22)00216-8
SLAS Discov, 2022, S2472-5552(22)12517-7
S6852 Gossypol Gossypol (BL 193) is an orally-active polyphenol isolated from cotton seeds and roots. This compound is a potent inhibitor of 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase with IC50 of 3.33 μM and 0.52 μM in cell-free assay, respectively. It also inhibits the binding of BH3 peptide to Bcl protein with IC50 of 0.4 μM and 10 μM for Bcl-XL and Bcl-2, respectively. This chemical induces apoptosis and cell growth inhibition in various cancer cells.
iScience, 2024, 27(10):110862
Cells, 2023, 12(18)2247
Cells, 2023, 10.3390/cells12182247
S8722 Samuraciclib (ICEC0942) hydrochloride Samuraciclib (ICEC0942) hydrochloride is a new, orally bioavailable CDK7 inhibitor with an IC50 of 40nM. The IC50 values for CDK1, CDK2, CDK5 and CDK9 were 45-, 15-, 230- and 30-fold higher. ICEC0942 (CT7001) promotes cell cycle arrest and apoptosis.
Int J Biol Macromol, 2025, 294:139117
NPJ Breast Cancer, 2025, 11(1):39
Nat Commun, 2023, 14(1):4003
S8405 RRx-001 RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. This compound triggers apoptosis and exhibits anticancer activity. It is also a downregulator of the CD47- SIRPα checkpoint pathway.
Cell Rep, 2023, 42(9):113035
Cell Mol Immunol, 2021, 18(6):1425-1436
Cancer Lett, 2021, 521:29-38
S9724 SZL P1-41 SZL P1-41 (compound #25) is a specific inhibitor of S-phase kinase-associated protein 2 (Skp2) that indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits Skp2 SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells. This compound causes higher apoptosis rates in cancer cells.
Cell Biology and Toxicology, 2025, 135
J Immunother Cancer, 2024, 12(12)e009444
Cell Death Discov, 2023, 9(1):364
S6877 EOAI3402143 EOAI3402143 is a dose-dependent inhibitor of Usp9x, Usp24 and Usp5 that increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice.
Cell Rep Med, 2023, 4(4):101007
Int J Biol Sci, 2021, 17(10):2417-2429
Int J Biol Sci, 2021, 17(10):2417-2429
S0149 C-DIM5 C-DIM5 (DIM-C-pPhOCH3) is an agonist of Nur77 (Nerve growth factor-induced Bα (NGFI-Bα)/nuclear receptor 4A1 (NR4A1)) which is an orphan nuclear receptor. This compound decreases survival and induces apoptosis in RKO colon cancer cells.
STAR Protoc, 2025, 6(1):103593
Cell Rep Med, 2024, S2666-3791(24)00234-9
Mol Psychiatry, 2022, 10.1038/s41380-022-01497-8
S8495 WT161 WT161 is a potent, selective, and bioavailable HDAC6 inhibitor with IC50 values of 0.4 nM, 8.35 nM and 15.4 nM for HDAC6, HDAC1 and HDAC2, respectively; shown to have >100-fold selectivity over other HDACs. This compound induces apoptosis.
Biomedicines, 2024, 12(6)1203
Nat Commun, 2023, 14(1):5051
Front Pharmacol, 2022, 13:780179
S9721 Farudodstat

Farudodstat(LAS 186323,ASLAN003) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity. ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional program in acute myeloid leukemia (AML) cells via activation of AP-1 transcription factors.

Front Cell Dev Biol, 2023, 11:1089945
iScience, 2022, 25(5):104293
bioRxiv, 2021, 10.1101/2021.06.28.450163
S6721 JG98 JG-98 is an allosteric inhibitor of Hsp70 that binds tightly to a deep pocket that is conserved in members of the Hsp70 family. JG-98 induces classical apoptosis features, including morphological changes consistent with programmed cell death and positive annexin staining. JG-98 exhibits anticancer activity.
Cell Commun Signal, 2024, 22(1):217
Cell Stress Chaperones, 2024, S1355-8145(24)00072-5
FEBS Open Bio, 2023, none
S9190 Oroxin B Oroxin B (Hypocretin-2), one of flavonoids isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent, selectively induces tumor-suppressive ER stress in malignant lymphoma cells and has antioxidant activity. This compound significantly inhibits proliferation and induce apoptosis, which may be strongly associated with the inhibiting COX-2/VEGF and PTEN/PI3K/AKT signaling pathway in SMMC-7721 cells, it potentially be used as a novel therapeutic agent for liver cancer.COX-2, VEGF, PI3K, and p-AKT expression levels are downregulated, while PTEN is upregulated after this chemical treatment.
Environ Pollut, 2023, 323:121306
Theranostics, 2022, 12(2):910-928
J Cancer, 2021, 12(7):2140-2150
S3984 Nordihydroguaiaretic acid (NDGA) Nordihydroguaiaretic acid (NDGA) is a phenolic antioxidant found in the leaves and twigs of the evergreen desert shrub, Larrea tridentata (Sesse and Moc. ex DC) Coville (creosote bush). It is a recognized inhibitor of lipoxygenase (LOX) and has antioxidant and free radical scavenging properties. Nordihydroguaiaretic acid (NDGA) is a cytotoxic insulin-like growth factor-I receptor (IGF-1R)/HER2 inhibitor and induces apoptosis.
Gut Microbes, 2025, 17(1):2518338
Gut Microbes, 2025, 2518338
npj Breast Cancer, 2024, 74
S3238 Resibufogenin Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. This compound exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. It induces apoptosis and caspase-3 and caspase-8 activity. This chemical increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
bioRxiv, 2025, 2025.07.17.665404
Research Square, 2024, 10.21203/rs.3.rs-3790060/v1
Phytomedicine, 2022, 102:154182
S6962 TPEN

TPEN (TPEDA) is a specific cell-permeable heavy metal chelator that induces apoptosis in NB4 cells via negatively regulating intracellular NO and Zn2+ signaling. This compound may be a potential therapeutic strategy for APL (acute promyelocytic leukemia). It induces DNA damage and increases intracellular ROS production and also inhibits cell proliferation.

J Cachexia Sarcopenia Muscle, 2025, 16(2):e13771
J Biol Chem, 2025, 301(10):110653
Biomaterials, 2021, 271:120720
S8543 ARN-3236 ARN-3236 is a potent, orally available and selective inhibitor of salt-inducible kinase 2 (SIK2) with IC50 of <1 nM, 21.63 nM and 6.63 nM for SIK2, SIK1 and SIK3, respectively. This compound induces apoptosis in cancer cells.
J Biol Chem, 2025, 301(8):110434
Int J Biol Sci, 2024, 20(1):312-330
Mol Oncol, 2022, 16(13):2558-2574
S6963 APTO-253

APTO-253 (LOR-253, LT-253) inhibits c-Myc expression and selectively induces CDKN1A (p21), promotes G0-G1 cell-cycle arrest, and triggers apoptosis in acute myeloid leukemia (AML) cells. This compound is also an inducer of KLF4 (Krüppel-like factor 4).

Annals of Translational Medicine, 2024, 113
Cell Commun Signal, 2023, 21(1):94
Cell Communication and Signaling, 2023, 94
S4513 RGD peptide (GRGDNP) RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. This compound induces apoptosis presumably through direct activation of caspase-3.
Pharmacological Research, 2024, 107269
Traditional Medicine Research, 2023, 50
Tradit Med Res, 2023, 8(9):50
S6894 BCH BCH (2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, LAT1-IN-1) is a selective and competitive inhibitor of system L amino acid transporter 1 (LAT1). This compound induces apoptosis in cancer cells.
J Immunother Cancer, 2023, 11(6)e006728
Cell Death Dis, 2023, 14(8):525
EMBO Rep, 2021, e51436
S1242 CPTH2 CPTH2 is a potent histone acetyltransferase (HAT) inhibitor modulating Gcn5p network. This compound induces apoptosis and decreases the invasiveness of a ccRCC cell line through the inhibition of KAT3B.
PLOS ONE, 2024, e0299145
Transl Oncol, 2021, 14(11):101196
Translational Oncology, 2021, 101196
S3300 Desoxyrhaponticin Desoxyrhaponticin (DC, DES), a stilbene glycoside from Rheum tanguticum Maxim. ex Balf. (rhubarb) which is a traditional Chinese nutritional food, is a fatty acid synthase (FAS/FASN) inhibitor. This compound is also a competitive inhibitor of glucose uptake with IC50 of 148.3 μM and 30.9 μM in rabbit intestinal membrane vesicles and in rat everted gut sleeves, respectively. It has apoptotic effect on human cancer cells.
Nat Metab, 2021, 10.1038/s42255-021-00479-4
Nature Metabolism, 2021, 1466-1475
S0765 MAZ51 MAZ51 is a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR)-3 (Flt-4) tyrosine kinase. MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells through phosphorylation of Akt/GSK3β and activation of RhoA. MAZ51 inhibits the proliferation and induces the apoptosis of a variety of non-VEGFR-3-expressing tumor cell lines.
Sci Rep, 2025, 15(1):1283
International Immunopharmacology, 2025, 114443
S6919 Brevilin A Brevilin A (6-O-Angeloylplenolina), a sesquiterpene lactone isolated from Centipeda minima, is a selective inhibitor of STAT3 and attenuates the JAKs activity by blocking the JAKs tyrosine kinase domain JH1. This compound induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation.
Frontiers in Pharmacology, 2022, 795613
Front Pharmacol, 2022, 13:795613
S6885 Ailanthone Ailanthone (AIL, Δ13-Dehydrochaparrinone), a natural anti-hepatocellular carcinoma (HCC) component in Ailanthus altissima, induces G0/G1-phase cell cycle arrest by decreasing expression of cyclins and CDKs and increases expression of p21 and p27. This compound triggers DNA damage characterized by activation of the ATM/ATR pathway. It induces apoptosis which is mitochondrion-mediated and involves the PI3K/AKT signaling pathway in Huh7 cells. This chemical is also a potent inhibitor of both full-length Androgen Receptor (AR-FL) and constitutively active truncated AR splice variants (AR-Vs, AR1-651) with IC50 of 69 nM and 309 nM, respectively.
Theranostics, 2024, 14(4):1371-1389
Theranostics, 2024, 1371-1389
S8988 Rhosin hydrochloride Rhosin (G04) hydrochloride (HCl) is a potent, specific inhibitor of RhoA subfamily Rho GTPases with Kd of ~ 0.4 uM. Rhosin hydrochloride induces cell apoptosis.
J Biol Chem, 2023, 299(6):104749
Carcinogenesis, 2022, bgac014
S9604 Lixumistat (IM156) Lixumistat (IM156) is a potent activator of AMPK that increases AMPK phosphorylation. It blocks oxidative phosphorylation (OXPHOS) through the inhibition of complex I and increases apoptosis. This compound ameliorates various types of fibrosis and inhibits tumors.
bioRxiv, 2024, nan
bioRxiv, 2024, 2024.09.16.613317
S9634 Phenoxodiol (Haginin E) Phenoxodiol (Haginin E, Idronoxil, Dehydroequol, NV 06, PXD) is an isoflavone analog with antineoplastic activity. It activates the caspase system, inhibits XIAP (X-linked inhibitor of apoptosis), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. This compound also inhibits DNA topoisomerase II.
Anticancer Res, 2018, 38(10):5709-5716
Anticancer Research, 2018, 5709-5716
S0444 Indibulin Indibulin (ZIO 301, D 24851, Zybulin) is an orally applied inhibitor of tubulin assembly with potent anticancer activity. This compound induces mitotic arrest and apoptosis.
Bioorg Med Chem, 2020, 28(20):115712
Bioorganic & Medicinal Chemistry Letters, 2020, 127635
S7867 Oleuropein Oleuropein is an antioxidant polyphenol isolated from olive leaf. It exerts antioxidant, anti-inflammatory and anti-atherogenic effects and suppresses the adipocyte differentiation in vitro. This compound inhibits PPARγ activity. It exerts anti-adipogenic effect through direct inhibition of PPARγ transcriptional activity. This chemical also inhibits aromatase. It induces apoptosis. Phase 2.
Front Endocrinol (Lausanne), 2024, 15:1354435
J Med Virol, 2019, 91(8):1440-1447
S9805 WM-3835 WM-3835 is a novel and high-specific small molecule Lysine Acetyltransferase 7 (KAT7, MYST2, HBO1) inhibitor, able to potently suppressed OS cell proliferation and migration, and leads to apoptosis activation.
Cell Mol Life Sci, 2025, 82(1):140
Cell Oncol (Dordr), 2025, 48(4):943-959
S3296 Hispidulin Hispidulin (Dinatin), an active natrual ingredient in a number of traditional Chinese medicinal herbs, exhibits inhibitory activity against the oncogenic protein kinase Pim-1 with IC50 of 2.71 μM. This compound induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells. It exerts anti-osteoporotic and bone resorption attenuating effects via activating the AMPK signaling pathway.
Evid Based Complement Alternat Med, 2023, 2023:9428241
S0817 SKI-V SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. This compound also inhibits PI3K with IC50 of 6 μM for hPI3k. It decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity.
Cell Death Discov, 2022, 8(1):48
S3168 cis-Resveratrol cis-Resveratrol (cis-RESV, cRes, (Z)-Resveratrol) is the Cis isomer of Resveratrol. Resveratrol is a natural phenolic compound with anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol is an inhibitor of pregnane X receptor (PXR) and an activator of Nrf2 and SIRT1 and may induce apoptosis. Resveratrol also inhibits a wide spectrum of targets including 5-lipoxygenase (LOX), cyclooxygenase (COX), IKKβ, DNA polymerases α and δ with IC50 of 2.7 μM, <1 μM, 1 μM, 3.3 μM and 5 μM, respectively.
J Gerontol A Biol Sci Med Sci, 2022, 77-8:1485-1493
S0354 Alsterpaullone Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. This compound also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. It induces apoptosis by activation of caspase-9. This chemical has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.
Cell Mol Life Sci, 2025, 82(1):311
S9665 Motixafortide (BL-8040, BKT140) Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ~1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
King's College London, 2023,
S4423 Emamectin Benzoate Emamectin Benzoate (EMB, MK-244) activates gamma-amino butyric acid (GABA) transporter. This compound induces of reactive oxygen species (ROS)-mediated DNA damage and apoptosis.
Viruses, 2025, 17(2)220
S3287 Rosamultin Rosamultin is a 19 α-hydroxyursane-type triterpenoid isolated from Potentilla anserina L. that inhibits HIV-1 protease. This compound has protective effects on H2O2-induced oxidative damage and apoptosis.
S6899 Licochalcone D Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. This compound inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. It inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. This chemical also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S0918 Ginkgolic acid C17:1 Ginkgolic acid C17:1 (GAC 17:1) inhibits constitutive activation of STAT3 through the abrogation of upstream JAK2 and Src. This compound can induce the substantial expression of PTEN and SHP-1. It induces apoptosis of tumor cells.
S3289 Daphnoretin Daphnoretin (Dephnoretin, Thymelol), a biologically active compound isolated from Wikstroemia indica C.A. Mey., is a protein kinase C (PKC) activator. This compound inhibits the proliferation, invasion, and migration of tumor cells and promote its apoptosis by regulating the activity of Akt signal pathway.
S3224 Cinobufagin Cinobufagin (Cinobufagine), an active ingredient of Venenum Bufonis, inhibits tumor development. This compound increases ATM and Chk2 and decreases CDC25C, CDK1, and cyclin B. It inhibits PI3K, AKT and Bcl-2 while increases levels of cleaved caspase-9 and caspase-3. Thus, this chemical induces cell cycle arrest at the G2/M phase and apoptosis.
S8961 Alobresib (GS-5829) Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. This compound inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. It also inhibits NF-κB signaling.
S3245 Nodakenetin Nodakenetin (NANI), a plant-derived coumarin isolated from Angelica decursiva, inhibits α-glucosidase, PTP1B, rat lens aldose reductase (RLAR), AChE, BChE, and β-site amyloid precursor protein cleaving enzyme 1 (BACE1). This compound alters the protein expression of Bax and Bcl-2, and prompts mitochondrial apoptosis. It exhibits anti-tumor activity.
S5554 Lanatoside C Lanatoside C is a cardiac glycoside with antiviral and anti-tumor activity. This compound induces G2/M cell cycle arrest and induces autophagy and apoptosis via attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways.
S0949 Cucurbitacin IIb Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. This compound exhibits anti-inflammatory activity and induces apoptosis. It is isolated from Hemsleya amabilis.
S0056 (E/Z)-BCI (E/Z)-BCI (BCI, NSC 150117) is an inhibitor of dual specific phosphatase 1/6 (DUSP1/DUSP6) and mitogen-activated protein kinase with EC50 of 13.3 μM and 8.0 μM for DUSP6 and DUSP1 in cells, respectively. (E)-BCI induces apoptosis via generation of reactive oxygen species (ROS) and activation of intrinsic mitochondrial pathway in H1299 lung cancer cells.
S9698 Ezatiostat Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). This compound activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis.
S6615 ATB 346 ATB 346, a novel hydrogen sulphide-releasing derivative of naproxen with remarkably reduced toxicity, inhibits COX activity. This compound is an anti-inflammatory agent that induces apoptosis of human melanoma cells.
S0103 ML327 ML327 is an isoxazole compound that blocks MYC expression and tumor formation in neuroblastoma. This compound also restores E-cadherin expression with In-Cell Western EC50 of 1.0 μM. It induces apoptosis.
S6882 HI-TOPK-032 HI-TOPK-032 is a potent and specific inhibitor of TOPK. This compound also reduces ERK-RSK phosphorylation, regulates of the abundance of p53, cleaved caspase-7, and cleaved PARP, and induces apoptosis in cancer cells.
S9054 Pectolinarin Pectolinarin is a major compound in Cirsium setidens with anti-inflammatory activity. This compound inhibits secretion of IL-6 and IL-8, as well as the production of PGE2 and NO. It also induces apoptosis via inactivation of the PI3K/Akt pathway.
S3576 TVB-3166 TVB-3166 is an orally-available, reversible, potent and selective inhibitor of fatty acid synthase (FASN) with IC50 of 0.042 μM in an in vitro biochemical assay. This compound induces apoptosis, and inhibits in-vivo xenograft tumor growth.
S8965 BO-264 BO-264 is a potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3) with IC50 of 188 nM and Kd of 1.5 nM. This compound specifically blocks the function of FGFR3-TACC3 fusion protein. It induces SAC-dependent mitotic arrest, apoptosis and DNA damage with antitumor activities.
S0407 XCT790 XCT-790 (Compound 12) is a potent and selective inverse agonist for estrogen-related receptor α (ERRα) with IC50 of 0.37 μM. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ. XCT-790 (Compound 12) significantly inhibits in vivo tumor growth and angiogenesis, and induces apoptosis.
S2942 EB-3D EB-3D is a potent and selective inhibitor of choline kinase α (ChoKα) with IC50 of 1 μM for ChoKα1. This compound induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells.
S9602 Elraglusib Elraglusib(9-ING-41) is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with antitumor activity. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK3β.
S5584 Citronellol Citronellol (Dihydrogeraniol, (±)-β-Citronellol), a constituent of rose and geranium oils, is used in perfumes and insect repellents. This compound can cause necrotic apoptosis of NCI-H1299 cells by up-regulating TNF-α, RIP1 / RIP3 activities, and down-regulating caspase-3 / caspase-8 activities. It also results in a biphasic increase in ROS production at 1 h and at 12 h in NCI-H1299 cells.
S4476 PCNA-I1 PCNA-I1 is a selective inhibitor of proliferating cell nuclear antigen (PCNA, a potential anticancer target). This compound selectively binds to PCNA trimers with Kd of ~0.2 to 0.4 μM. It inhibits the growth of tumor cells of various tissue types with IC50 of ~0.2 μM. This chemical induces DNA damage and apoptosis in both LNCaP and PC-3 cells. It also induces autophagy in PC-3 cells.
S0445 SC-43 SC-43, a sorafenib derivative, is an agonist of Src-homology protein tyrosine phosphatase-1 (SHP-1/PTPN6) and reduces liver fibrosis. This compound reduces p-STAT3 and induces apoptosis with anti-tumor activity.
S0884 RA-9 RA-9 is a cell-permeable, potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity profile and anticancer activity. This compound selectively induces apoptosis in ovarian cancer cell lines.
S1273 Amarogentin

Amarogentin (AG), a secoiridoid glycoside mainly extracted from Swertia and Gentiana roots, exhibits anti-oxidative, anti-tumour, and anti-diabetic activities. This compound is an agonist for the bitter taste receptor TAS2R1 and inhibits in LAD-2 cells substance P-induced production of newly synthesized TNF-α. It induces apoptosis in human gastric cancer cells (SNU-16) through G2/M cell cycle arrest and PI3K/Akt signalling pathway. This chemical interacts with the α2 subunit of AMP-activated protein kinase (AMPK) and activates the trimeric kinase with EC50 of 277 pM.

S3256 Tectochrysin Tectochrysin (Techtochrysin, NSC 80687) is one of the major flavonoids of Alpinia oxyphylla Miquel. This compound significantly increases the expression of DR3, DR4 and Fas and inhibits activity of NF-κB. It induces apoptotic cell death.